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The CAPRISA 004 trial demonstrated the safety and a 39% efficacy of a 1% tenofovir 
(TFV) gel for the prevention of HIV-1 acquisition in young African women.  It was subsequently 
shown that women assigned to the TFV arm who became infected had higher viral loads, slower 
anti-HIV-1 antibody avidity maturation, and higher Gag-specific IFN-γ+ CD4+ T cell responses; 
although replication capacity, as measured by Gag-Pro recombinant viruses, did not differ 
between arms.  We thus aimed to investigate if there were differences in Envelope function, or 
TFV susceptibility, which may be selected for during transmission in those who became infected 
despite being assigned to the TFV arm.   
Viruses from 39 out of 48 recently HIV-1 infected individuals from the trial (matched on 
time post-infection and the presence of protective HLAs) were isolated.  Isolate env genes were 
sequenced using a single genome amplification approach and were compared to plasma 
sequences from the same time-point.  To evaluate phenotypic characteristics of env, inhibition 
assays were performed using the following inhibitors: tenofovir, maraviroc, T20, PSC-RANTES 
and anti-CD4 antibody clone SK3.  In addition, envs for 19 participants were cloned and used to 
generate pseudoviruses which were evaluated for entry efficiency.   
Viral isolates were identical or very similar to viruses in circulation in vivo; however had 
a lower diversity, indicating that they were representative of in vivo virus but did not reflect the 
entire quasispecies in plasma.  The TFV arm viruses were not more resistant to TFV than those in 
the placebo arm.  A comparison of variable loop characteristics, distance to a consensus 
representative of viruses circulating in the region, and sensitivity to inhibitors or entry 
efficiencies of the viruses, also found no difference in genotypic nor phenotypic properties 
between study arms.  When assessing the impact of viral phenotype on markers of disease 
progression, it was found that sensitivity to inhibitors did not contribute to VL or CD4+ count in 
this cohort.  To evaluate envelope in isolation of the rest of the genome, pseudoviruses were 
generated from 11 participants.  We found that PSV entry efficiency did not correlate with VL at 
isolation, 3 months post-infection and set-point, or with CD4+ counts at set-point.  However, 
pseudovirus inhibitor sensitivities were significantly different to those of isolates for the 
inhibitors T20, anti-CD4 antibody SK3 and PSC-RANTES. 
Overall, the isolate env genotypic and phenotypic characteristics investigated in this study 
did not differ between trial arms.  Interestingly, pseudoviruses showed significant differences in 
their sensitivity to entry inhibitors when compared to their corresponding isolate, highlighting 
the importance of caution when interpreting data from in vitro studies, and motivates for further 
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Human Immunodeficiency Virus (HIV-1), the causative agent of Acquired Immune Deficiency 
Syndrome (AIDS), has claimed more than 39 million lives since it was first described in 1981 (1).  
In 2013, 2.1 million new infections globally brought the total number of people living with HIV-1 
worldwide to 35 million.  Of these people infected with HIV-1, the majority live in Sub-Saharan 
Africa which contributes to almost 70% of new infections.  Women disproportionately carry the 
burden of HIV-1 infection in most regions in the world.  It is estimated that in sub-Saharan Africa, 
three to six times as many young women are infected than young men (1).  Many socioeconomic 
factors play a part in this disease burden disparity; most notably, cultural attitudes towards sex 
(2, 3), gender inequality (4), intergenerational sex (5), concurrent sexual partners (6), gender-
based violence (7), poor education, poverty and unemployment (8); all of which increase 
vulnerability to HIV-1 infection.  Aside from the socioeconomic factors, women have been found 
to more biologically susceptible to infection with heterosexual transmission of HIV-1 from male 
to female being up to eight-fold as efficient as from female to male (9–12).  Factors which have 
been identified as contributing to the higher efficiency of heterosexual transmission of HIV-1 
from male to female include: 
 
i. The female genital mucosa has a large surface area through which transmission of 
HIV-1 can occur (9); 
ii. The epithelial barrier of the endocervix and uterus is only a single layer of cells thick 
and has been shown to be more susceptible to the transmission of HIV-1 (13, 14); 
iii. The vaginal mucosa is susceptible to hormonal changes which occur during the 
menstrual cycle and when hormonal contraceptives are used (15–18). More 
specifically, thinning of the epithelial lining and decreased cervical mucous resulting 
in a reduced barrier to infection; 
iv. Intercourse can lead to micro-abrasions which lower the barrier to infection.   
v. There is a higher likelihood of genital ulcer disease and undiagnosed sexually 
transmitted infection (STIs) in women as well as bacterial vaginosis which men do not 
experience (15, 18, 19). 






HIV-1 was discovered during a time when major breakthroughs were being made in the field of 
vaccinology and it was thought that a vaccine would be available within a few years.  However, 
35 years later, we are still without an effective vaccine.  Current management of the global burden 
of disease promotes safer sex practices such as abstinence, condom use and limiting the number 
of sexual partners, voluntary counselling, voluntary and frequent testing, antiretroviral therapy 
(ART), treatment of STIs, and male circumcision [reviewed in (22)].  The last decade has seen an 
expansion of biomedical interventions including pre- and post-exposure prophylaxis (PrEP and 
PEP, respectively); as well as microbicides (detailed in section 1.5).  Microbicides are of particular 
relevance to women, providing them control over their protection from acquiring HIV; especially 
important in situations where condom-use cannot be negotiated.   
 
This chapter will review HIV-1 transmission, the biomedical intervention trials including the 
CAPRISA 004 1% Tenofovir microbicide gel (the first successful clinical trial to demonstrate 
protection by a microbicide).  Finally the focus of this thesis will be how HIV phenotype affects 
transmission and disease progression, outlining why HIV-1 envelope (env) is a gene of interest. 
 
 
1.2 HIV-1 transmission and disease progression 
 
The HIV-1 transmission bottleneck 
During heterosexual transmission of HIV-1, only a subset of viruses from the diverse quasispecies 
within the donor will be transmitted and will establish productive infection (23–27).  In 
approximately 80% of cases this transmission bottleneck results in a single virus initiating clinical 
infection, known as the transmitted/founder (T/F) virus.  
  
Intravenous and intrarectal dose-challenge studies in Indian Rhesus macaques resulted in a 
genetic bottleneck similar to that seen in humans and HIV-1.  Simian Immunodeficiency Virus 
(SIV) challenge studies in monkeys have thus been used as a model system to aid in investigating 
HIV-1 transmission in humans.  In macaques, intravenous inoculation or high dose challenges 
delivered mucosally resulted in a larger proportion of multi-variant virus infections.  In humans, 
studies have found a higher multiplicity of infection in injection drug users (IDU), men who have 
sex with men (MSM) and heterosexual transmission in the presence of high genital inflammation, 
where 60% (28), 36% (29), and 57% (30) of infections were due to multiple variants, 
respectively.  Susceptibility to multivariant HIV-1 infection can increase in cases such as in penile-
anal transmission (where there is a higher availability of target cells) [reviewed in (31)] and 




which HIV-1 circumvents the mucosal barrier altogether may also lead to multivariant 
transmissions as seen in some IDU studies (28), although this was not seen in all studies (32).  
Together, this data suggests that the mucosal barrier is largely responsible for the genetic 
bottleneck and that multivariant transmission is associated with modes of transmission where 
the risk of HIV-1 acquisition is increased.   
 
Disease progression and viral load 
Viral load (VL) is the number of copies of HIV-1 RNA per millilitre of blood and it fluctuates along 
the course of HIV-1 infection (33, 34), which is characterised by a period of acute infection 
followed by chronic infection.  During acute infection, the VL reaches a peak, after which the VL 
declines due to viral suppression by the host immune responses.  After acute infection (~3 
months post-infection), the chronic phase of infection sets in, which is characterised by clinical 
latency and stable VL over time, termed “set-point”.  The VL measurement at set-point is most 
reliably measured around 12 months post-infection and is used as a predictor of disease 
progression (35, 36) since set-point VL has been positively correlated with time to AIDS-defining 
illness or CD4+ T cell count below a certain critical value (currently 350 cells per microliter of 
blood) (37).  Some virological factors have been shown to affect disease progression as well, for 
instance, multi-variant infections.  Multi-variant infections have been correlated with higher VL 




1.3 Evidence for selection at the mucosal barrier 
 
The fact that there is a bottleneck raises the question of whether transmission represents a 
stochastic event in which each donor virus has an equal but very low chance of making it across, 
or whether the bottleneck represents a selection event where viral variants that have biological 
properties favourable to establishing new infections are favoured.  For HIV-1 infection to become 
established, the transmitted variant must be present in the mucosa at the site of transmission, 
must be able to cross the mucosal barrier to make contact with target cells in the recipient 
efficiently establish a local focus of infection and, finally, systemic infection.  While a large part of 
transmission may be based on chance, there are a number of factors pointing to an element of 
selection during transmission. 
 
Studies showing that transmitted viruses share common phenotypes, and that they differ from 




transmission.  A study using infectious molecular clones (IMCs) showed that transmitted variants 
are more infectious and have 1.9-fold more Envelope glycoprotein (Env) on their surfaces per 
virus particle than viruses from chronic infection.  Transmitted viruses also share the common 
phenotype of CCR5 co-receptor usage (23, 38–43), and subtype A and C, but not subtype B, have 
been found to have more compact envs (i.e. shorter variable loop regions and fewer N-linked 
glycosylation sites) (24, 44–46).  While  one study found that T/F viruses were more resistant to 
the antiviral cytokine interferon alpha (subtype B viruses) (47) than viruses from chronic 
infection, a more recent study was unable to reproduce this finding (48).   
 
Serodiscordant couples (where one partner is HIV-1 infected and the other is not) and 
transmission pairs (when the seronegative partner in a serodiscordant pair becomes HIV-1 
infected) allow for the study of donor and recipient viruses, and offer insight into which factors, 
both viral and immunological, affect transmission.  In transmission pairs, where donor viruses 
were compared to early viruses in the recipient, transmitted variants were shown to be more 
sensitive to neutralization by the donor serum (49).  Furthermore, Carlson et al. observed the 
favoured transmission of variants with amino acid identities closer to the cohort consensus than 
what chronic viruses were in the donor (50).  Since consensus sequences represent viruses which 
are ‘fitter’ within a given environment (in the case of transmission, viruses which have favourable 
characteristics that allow them to be transmitted more easily), this suggests that transmitted 
viruses have a greater replicative fitness than viruses from chronic infection.  Moreover, 
participants with a higher risk of transmission showed a reduction in this selection bias for 
consensus-like amino acids.  For example, there was a weaker bias for transmission of consensus 
amino acids during transmission to women than to men, but men with inflammation or genital 
ulcers show a similar selection bias to that of women.  Also by studying transmission pairs, Boeras 
et al. showed that the transmitted variant is not the predominant variant in the genital tract (51); 
indicating that there is selection of a more favourably transmissible variant.      
 
The basis of selection during mucosal infection is complex with many factors contributing to the 
establishment of clinical infection; such as the target cell population at the mucosa and the level 
of inflammation present at the time of infection.  From these studies, it is evident that several 
properties of HIV-1 Env glycoprotein are implicated in selective transmission, making it a suitable 
candidate for investigation as a factor that may increase the chances of infection by certain viral 







1.4 The importance of Envelope in the transmission of HIV-1 
 
Cell-free virus transmission 
The Env glycoprotein of HIV-1 is responsible for attachment of virions to target cells, fusion of the 
viral and host cell membranes and entry of the viral capsid into the cell (52).  The env gene 
encodes gp160 which consists of a signal peptide, gp120 and gp41, subsequently cleaved by the 
host endoproteases (53–55) in the Golgi into gp120 and gp41.  This occurs as the proteins are 
exported to the cell surface prior to viral assembly at the cell membrane and budding.  It is 
important to note that cleavage of Env into gp120 and gp41 is not required for Env export onto 
the cell surface (55).  On budding and mature virions, fully processed Env spikes occur as Env 
trimers on the virion surface.  Each trimer consists of the gp120 non-covalently attached to gp41 
(56, 57).  Gp41 is embedded in the viral membrane and provides anchorage of Env to the virion 
surface.  To initiate the entry process, gp120 binds to the CD4 receptor on target cells which 
causes a conformational change in the Env complex, allowing for co-receptor engagement.  After 
CD4 and co-receptor binding, the N-terminal domain of gp41 (membrane fusion peptide) 
penetrates the cell membrane after which the two heptad repeat regions, HR1 and HR2, interact 
(fold back on each other) and form a hairpin structure. This results in fusion of the viral and cell 
membranes, and subsequently, the viral capsid is released into the cell.   
 
 
Cell-associated virus transmission 
In contrast to cell-free transmission, which relies on stochastic interaction between cell surface 
receptors and free-floating virions in the extracellular space, cell-to-cell transmission (fig. 3) 
takes advantage of the biological need for direct contact between immune cells as a means of 
communication.  While the mechanisms of cell-to-cell spread are poorly understood, it has been 
shown to be more efficient than cell-free transmission and has long been proposed as an 
important determinant in viral dissemination (58–60).  Cell-to-cell transmission depends on the 
interaction of receptors in donor- and target cell membranes and the subsequent formation of a 
virological synapse (VS) across which viruses traverse (61–67).  Infected cells have been shown 
to transfer virus particles across a VS to T cells at a high multiplicity of infection (60, 68–70).  
 
It has been shown in tissue culture models that high-multiplicity of infection resulting from cell-
to-cell contact increases the probability that a virus may escape drug inhibition.  This can occur if 
the number of infecting viral particles exceeds the effective drug concentration within the cell 
(71, 72).  It is a particular effective strategy of replication in the face of Tenofovir (TFV), which is 




of TFV within immune cells in the mucosa could have been overcome by this mode of 
transmission.  Some groups have shown that cell-to-cell spread allows for efficient replication of 
the virus in the face of neutralizing antibody immune responses (60, 68, 72–74).  However there 
is contradicting evidence that this method of spread is not a mechanism to evade antibodies or 
other entry inhibitors (63).   
 
 
Figure 1.1.  Cell-to-cell spread facilitates multiple infections per cell.  One mechanism by 
which HIV can overcome intracellular drug concentrations is by cell to cell spread.  Infected cells 
are represented in red; uninfected cells in grey; blue hexagons represent viruses (encircled blue 
hexagon= cell-free virus); crosses represent a viral integration event blocked by a drug molecule; 
wavelets represent provirus (productive infection) and dotted circles outside of cells represent 




Env is a key component in cell-to-cell transmission as it mediates the initial contact of infected 
cells (which have gp120 exposed on their surfaces) to uninfected target cells, and the formation 
of a VS (61).  Thus, Env engagement with cell surface receptors and co-receptors is essential for 
efficient transmission and dissemination and preventing this from occurring could be an effective 
way to prevent the establishment of infection.  
 
Target cell tropism 
HIV-1 most commonly makes use of one of two co-receptors to enter target cells:  C-C chemokine 
receptor type 5 (CCR5) and C-X-C chemokine receptor 4 (CXCR4).  CCR5 is commonly found on 
macrophages, dendritic cells, activated T-lymphocytes and, to a lesser extent, monocytes (in 
which case the virus is R5-tropic), while CXCR4 is found on T-lymphocytes, thymocytes and 
immune precursor cells (making the virus X4-tropic).  Binding of Env trimers to the CD4 receptor 
via the V1/V2 loop of Gp120 causes a conformational change in Env which, in turn, repositions 
the V1/V2, and the V3 loops.  The Env trimer then binds the chemokine receptors on the target 
cell surface [reviewed in (75)].  The V3 region of gp120, has been implicated as a determinant of 




1.5 Antiretroviral therapy and prevention 
 
The different classes of anti-retroviral therapy (ART) are able to block or inhibit essential steps 
of the HIV-1 replication cycle (Table I) thereby decreasing HIV-1 VL to below levels of detection, 
and slowing down disease progression.  Although historically ART refers to these drugs used 
individually or with one other drug to treat HIV-1 infection, the current standard of care is 
combination, multi-drug therapy also known as Highly Active ART (HAART).  HAART employs the 
use of three or more drugs from at least two different drug classes in combination.  In South Africa, 
the current first line regimen consists of Tenofovir Disoproxil Fumarate (TDF), emtricitabine 
(FTC), and efavirenz (EFV) in combination.  Combination therapy has the added benefit of 
deferring the emergence of drug resistance by blocking multiple steps of the HIV-1 replication 
cycle simultaneously; ensuring that variants with resistance to one of the drugs are still not able 
to replicate. 
 
Table 1.1.  Antiretroviral drug classes and the steps of the viral life cycle acted on*   
Step of HIV-1 
replication cycle 
inhibited 
ARV drug class Abbreviation 







Fusion inhibitors FIs Enfurvitide (T20) No 
Co-receptor 
inhibitors 
















NNRTIs Efavirenz (EFV) 




INIs Raltegravir (RAL) 3
rd line 







2nd line and after 
*This table was modified from the table provided on the AIDS info website, National Institutes of Health, 
USA (78) and the Scientific Electronic Online Library South Africa . 
 
 
A meta-analysis of ten studies showed that transmission correlated directly with VL in ART-naïve, 
serodiscordant couples (79) indicating that VL is a determinant of transmission.  This finding 




individuals to prevent them from transmitting HIV-1.  Thus, in HIV-1 infected patients on ART, 
successful treatment leads to a reduction in their plasma VL, an increased CD4 count over time 
and also reduces the risk of transmission.  TasP has been shown to be effective in both 
serodiscordant couples (9, 80–85) and from mother to child during childbirth and breastfeeding 
(86–88) if the infected individual’s VL is suppressed below 50 copies/mL. 
 
ART has also been found to have prophylactic efficacy when administered to uninfected 
individuals either directly after an exposure event (post-exposure prophylaxis or PEP) or before 
an expected exposure event (pre-exposure prophylaxis or PrEP).  PrEP can be administered in a 
number of ways, including oral doses of ARVs and as topical microbicides.  Numerous efficacy 
trials have been conducted using both oral, topical and injectable PrEP as a means of preventing 
HIV-1 acquisition.  Of these, the pre-exposure prophylaxis initiative (iPrEx) trial  (89), Partners 
PrEP (90) and TDF2 (91) studies resulted in a high degree of protection ranging from 44- to 75% 
in MSM (89) and heterosexual (90, 91) serodiscordant couples, respectively.  Adherence is a 
major challenge in PrEP and is thought to account for the failure of some.  Lack of protection due 
to lack of adherence was evident for example in the FEM-PrEP (daily oral PrEP) and MTN 003 
(VOICE; daily oral and vaginal PrEP) trials which were discontinued early due to lack of evidence 
for protection against HIV-1 acquisition in women (92, 93).  A summary of the successful efficacy 
trials, dosing regimens, and efficacy in high adherers is summarised in table 1.2.  In order to 
overcome problems with adherence, trials investigating Cabotegravir, a long-acting integrase 

































Daily oral FTC/TDF 
MSM & transgender 
women 














Adherence was high 
throughout the 
study 





Daily oral FTC/TDF 
Young heterosexual 
men and women 
63% 
Adherence was high 
throughout the 
study 





Pericoital dosing of 
1% TFV gel 









Heterosexual women 27% 
High in women >21 
y/o: 56%  








Heterosexual women 31% 
High in women >21 
y/o: 37% 




* CROI, Boston, MA, USA. February, 2016. 
 
 
These studies provided evidence that ART, when taken correctly, has the potential to affect 
transmission at the individual level and also, possibly, the course of HIV-1 incidence at the 
population level (97, 98).  Reducing the rate of infection in women is essential to changing the 
current trajectory of the HIV-1 epidemic in Africa.  Microbicides in particular may be of benefit 
for use by women in order to take control over their own protection.  Microbicides are a topical 
form of PrEP and can be made into a number of formulations (such as gels, sponges or rings) to 
contain either compounds with broad antiviral activity or HIV-specific ARVs.  These can be 
inserted into the vagina or rectum in order to prevent transmission of HIV-1 (or other STIs 
depending on the formulation).  Efficacy trials have shown that those microbicides containing 
compounds with non-specific antiviral activity (such as PRO2000, SDS and nonoxylin-9) have 
been ineffective at preventing acquisition of HIV-1 (99, 100).  On the contrary, some of these non-
HIV-1 specific microbicides lead to damage of the mucosa (101) and recruitment of HIV-1 target 





However, microbicide trials with HIV-specific ARVs have yielded some success (see table 1.2).  
The first of these tested a microbicide containing Tenofovir (TFV).  TFV is an adenosine nucleotide 
analogue that terminates DNA strand synthesis by the viral reverse transcriptase enzyme because 
it does not have a 5’ phosphate for the next incoming base to react with. Hence, no phosphodiester 
bond can be formed and the process of reverse transcription is disrupted.  This makes it potent 
against retroviruses (103, 104).  The CAPRISA 004 microbicide trial was the first to demonstrate 
the success of a vaginal microbicide in preventing the acquisition of HIV-1 and also herpes 
simplex virus type 2 (HSV-2) (95, 105).  In sub-Saharan Africa, up to 80% of sexually active 
women and 50% of sexually active men are infected with HSV-2, which is the most common cause 
of genital ulcer disease and which, in turn, can increase the risk of HIV-1 acquisition.   
 
One advantage of microbicide use over oral PrEP is that uninfected individuals are only exposed 
to the ARVs at the mucosal sites of transmission and hence they have higher levels of the drug at 
the site of infection, while experiencing fewer adverse systemic effects associated with their use.   
 
It is essential that drug levels (systemic or in the mucosa) are maintained at optimal levels in 
order to achieve protection.  This was supported by observations from the CAPRISA 004 (see 
section 1.6) and FACTS 001 cohorts (106–108), where the degree of protection was linked to 
adherence of participants to the treatment regimen.  There is a necessity to identify dosing and 
counselling strategies which would encourage participants to adhere to treatment regimens so 
that effectiveness of treatments can be accurately determined.  
 
Non-adherence to treatment regimens has also been found to be associated with resistance of the 
virus to ARVs (109).  Resistance to TFV is associated with mutations in the reverse transcriptase 
(rt) gene which has been shown to confer viral resistance in cell culture (110, 111) and in patients 
on ART (109).  The most common of these mutations is the K65R point mutation which occurs in 
23-65% of people failing first-line ART containing TFV in South Africa (112–115).  In addition to 
the emergence of resistance due to drug exposure (116), these resistance mutations are able to 
be transmitted and confer viral resistance in recipients who become infected with these viruses 
(117).  Selection of TFV-resistant T/F viruses, which may occur due to the presence of the drug 
at mucosal sites, or the development of resistance by breakthrough viruses during the 
establishment of local infection while drug concentrations are suboptimal would pose a threat to 
the efficacy of TFV-based microbicides.  Thus far, however, no transmitted resistance due to the 
use of TFV-based microbicides has been observed (95, 118).  Hence, microbicides represent a 





1.6 The CAPRISA 004 1% tenofovir gel Microbicide Trial 
 
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) conducted a phase IIb 
randomised, placebo (PLB)-controlled trial testing the safety and effectiveness of a 1% tenofovir 
gel formulation in women from rural and urban areas in Kwa-Zulu Natal, South Africa (95).  A 
total of 889 females between the ages of 18 and 40 years and who were sexually active were 
requested to use one dose of the microbicide gel 12h before sexual intercourse and one dose as 
soon as possible within 12h after with no more than two doses in a 24h period (BAT24).  The 
study provided the first evidence that coitally-linked dosing of the microbicide gel lead to a 
reduction in the acquisition of HIV-1 (fig. 1.2).  Overall, there was a 39% reduction in acquisition 
in women from the TFV arm (5.6 infections per 100 women-years compared to 9.1 infections per 
100 women-years in the PLB arm) and a 54% lower chance of acquiring the virus when adherence 
to the treatment regimen was high.  A phase III study for the licensure of 1% Tenofovir gel (FACTS 
001) showed that treatment had no overall protective effect but that the effectiveness of TFV gel 
was highest in high adherers who reported use of the gel in greater than 72% of sex acts (only 
20% of the cohort) (108).  Of those with self-reported high adherence, detectable TFV in their 




Figure 1.2.  Probability of infection over time by trial arm in the CAPRISA 004 trial.  Figure 






A follow up of the women in the CAPRISA 004 cohort showed that, in participants who became 
infected despite the use of TFV, VLs were significantly higher at one year post infection when 
compared to participants of the PLB arm (HIV-1 VL log 4.30 versus 3.72 copies/ml; p=0.02) (119).  
The VLs of participants followed this trend throughout the first two years of infection.  
Interestingly, participants from both arms had similar disease progression as measured by time 
to plasma CD4+ T cell counts <350 cells/µL. 
 
 
1.7 Explaining the sub-optimal efficacy of tenofovir gel 
 
The characterisation of breakthrough infections reported in this study formed part of the 
Tenofovir gel Research for Advancing Prevention Science (TRAPS) Program, which was 
established to address questions that stemmed from the CAPRISA 004 Trial; including why only 
a 39% reduction in HIV-1 acquisition was observed in the drug arm of the trial.   
 
One hypothesis was that pre-infection inflammation and immune activation resulted in target 
cells being readily-available for infection at the site of transmission, thereby reducing the 
effectiveness of 1% TFV gel.  Naranbhai et al. (2012) found that participants who became infected 
while on the trial, regardless of the trial arm, expressed a unique pattern of innate 
proinflammatory and T cell homeostatic cytokines as well as higher proportions of activated NK 
cells in their blood plasma before infection (120).  Similarly, Masson et al. (2015) have shown that 
higher levels of genital inflammation correlated with an increased risk of HIV-1 acquisition in 
these women, regardless of trial arm (21).  The study found that raised levels of proinflammatory 
cytokines were persistent for about a year prior to infection.  While the reason for this persistent 
inflammation remains unclear, elevated levels of inflammation at the genital mucosa and overall 
systemic innate immune activation contributed to the risk of acquiring HIV-1 in this cohort. 
However, since neither genital inflammation, nor innate immune activation were found to be 
different between trial arms, this cannot explain the suboptimal efficacy of TFV gel. 
 
Adherence to the treatment regimen is a large contributing factor to the efficacy of all treatment 
and prevention methods and contributes to the transmission of resistant variants (see section 
1.5).  However, the high adherence group in the TFV arm of CAPRISA 004 still had suboptimal 
protection from infection (54%).  Therefore, low adherence only partially explains the sub-
optimal efficacy of the 1% TFV gel.  In addition, no resistance was detected in CAPRISA 004 
participants (95, 118) indicating that breakthrough infections were not the result of resistant 




with resistance screening in other TFV-based PrEP trials where no resistance to TFV was found 
(89–91, 112).  These findings highlight the necessity of tweaking dosing strategies to confer 
optimal protection and present the challenge of elucidating why viruses were still able to be 
transmitted to participants despite high adherence to treatment.  
 
 
1.8  Viral characteristics can influence disease progression 
 
In vivo, the replicative fitness of a virus will depend on the interplay between the host’s immune 
system and viral characteristics, such as the virus’ ability to enter different target cells, the 
efficiency of the entry process, the efficiency of integration of the viral genome; and, how rapidly 
the virus can replicate and disseminate once it has entered the target cell.  Firstly, disease 
progression varies with the infecting subtype of HIV-1.  Subtype D infection is associated with 
faster disease progression than subtype A independently of viral load (121, 122), while subtype 
C infection is associated with faster disease progression than subtype B (123).  Furthermore, a 
switch in target cell tropism over the course of infection, from R5- to X4-tropic HIV-1, has been 
shown to be associated with disease progression to AIDS-defining illness (41, 124, 125). 
 
In elite controllers (individuals who suppress their VL to below 50 RNA copies/mL of plasma in 
the absence of ART) whose viruses have attenuated Gag (126, 127), Pol (128), Env or Nef (129) 
protein function, progression to AIDS-defining illness is slow.  This diminished protein function 
is due to selection pressure by effective CD8+ T-cell responses mounted by each individual’s 
protective human leukocyte antigens (HLAs) as part of the adaptive immune response to HIV-1 
during the natural course of infection.  It has also been shown that these attenuated strains can 
remain attenuated in the absence of immune pressure when transmitted to individuals who lack 
these protective HLA genes, as evidenced by a lower VL and more favourable disease progression 
in these patients (130, 131).  Furthermore, there is evidence that infection with viruses with 
reduced replication capacity was associated with subsequent elite control (127).  In vitro 
replicative capacity has been found to be a determinant of VL in chronic infection (132) and the 
replication capacity of recombinant viruses containing Gag-Pro genes from acute infection was 
shown to correlate with VL set-point and CD4 T cell decline (133).  In addition, the VLs in HIV-1 
recipients in both early infection and at set-point can be predicted by donor VLs (134, 135).  
Together, this evidence suggests that viral characteristics can have a large impact on disease 
progression, and that some of these characteristics which are observed during acute or early 




1.9 Explaining the viral load differences between tenofovir and placebo 
recipients 
 
A higher VL at set-point was observed in those who became infected in the TFV arm.  Infection 
with multiple variants has been correlated with a higher VL at set-point and faster disease 
progression (30, 136, 137) and hence could possibly have explained the increased VL.  However, 
Valley-Omar and colleagues showed that the genetic bottleneck in breakthrough infections was 
not affected by the presence of TFV (138).  In the TFV arm 77% of infections were the result of a 
single variant; similar to the 93% in the PLB arm (P=0.37) and  80% in other subtype C studies 
(27, 138).  Therefore, alteration of the mucosal barrier allowing more than one viral variant to be 
transmitted was not likely to be the reason for the increase seen in the VL at set-point.   
 
Laeyenndecker et al. (2015) evaluated the antibody response to HIV-1 infection in the CAPRISA 
004 cohort and found that women who became infected while assigned to the TFV arm showed 
slower antibody avidity maturation to gp120 (139); that is, the combined strength of antibody 
binding due to multiple interaction between the antibody and antigen (140).  This finding mirrors 
the delayed antibody avidity seen in rhesus macaques following infection despite oral TFV PrEP 
(141).  Both studies showed no difference in antibody titre between the trial arms.  Interestingly, 
the macaque studies showed lower peak viremia during acute infection (which was not seen in 
the CAPRISA 004 cohort at the time of seroconversion) and reduced systemic inflammation in 
animals receiving PrEP (141, 142).  Whether delayed antibody avidity maturation may have led 
to higher VL at set-point in both macaque and human studies was not shown and remains 
unknown. 
 
An alternative hypothesis is that TFV selects for viruses that replicate better in the mucosal 
environment, establishing a greater local focus of infection that can overcome the TFV barrier and 
subsequently spreading to the lymph nodes to establish systemic infection.  As in vitro replication 
capacity has been shown to correlate with in vivo VL (127, 130, 132, 133, 143–145), HIV-1 Gag, 
Gag-Protease and Nef function were investigated as the possible underlying factors for an 
increased replicative capacity and VL (146).  Increased Nef activity, for example, has been shown 
to downregulate CD4 (147) and major histocompatibility complex (MHC) class I (148).  The 
replication capacity of Gag-Pro recombinants derived from T/F viruses from CAPRISA 004 
participants correlates with set-point VL; an observation that was also made using T/F Gag 
recombinants from a cohort in Zambia (144).  However, no significant differences were found in 
in vitro Gag-Pro mediated replication capacity or Nef function of T/F viruses between the 




the increased VL at set-point; and, if the cause was due to characteristics of the transmitted 
viruses, which characteristics may have been the reason for the increased VL.   
 
 
1.10 Study rationale 
 
Several studies have shown a relationship between HIV-1 replication ex vivo and plasma VL (132, 
143, 149, 150).  In addition, the Env glycoprotein has been shown to be an important determinant 
of ex vivo viral replicative fitness (76).  In this study we investigated whether the presence of TFV 
in target cells selected for viruses with a certain Env phenotype at the time of transmission.  We 
hypothesize that an altered Env phenotype in TFV arm virions, compared to the Env phenotype 
of PLB arm virions, conferred a replicative advantage which allowed viruses to replicate to a 
higher VL at set-point.  To do this we compared the Env properties of early breakthrough viruses 
from TFV recipients to early viruses from PLB recipients from the CAPRISA 004 microbicide trial.   
 
 
1.11 Significance of this research 
 
Microbicides need to block the transmission event and hence there is a need to identify the 
characteristics of the earliest viruses present in individuals who become infected despite the use 
of prophylaxis.  Inferences can be drawn from early viruses about the transmitted viruse(s) that 
were able to overcome the barrier of protection and those that may lead to high VL later on during 
infection.  In the CAPRISA 004 cohort, preliminary studies show that VLs in women who become 
infected while assigned to the TFV arm are higher than those assigned to the PLB arm.  Research 
is needed to understand the underlying mechanisms associated with the increase in VL.  In 
addition to informing the improvement of microbicides, information about acute-phase infection 
and transmitted viruses will also aid in vaccine design efforts (23, 151).  
 
 
1.12 Aims and specific objectives 
 
The aim of this study was to characterise the phenotypes of the viral Env proteins from early 
viruses from both the PLB and TFV arm of the CAPRISA 004 trial; and to determine whether there 








1) To isolate early viruses (<3 months post-infection) from participant plasma. 
 
Approach:  CD44 microbeads were used to isolate viruses from infected plasma by 
magnetic separation.  The resultant eluate, containing virus, was used to inoculate 
cultures of primary cells.  Primary cells from three different donors were isolated and 
pooled and subsequently stimulated under three different conditions before being 
infected.   
 
2) To assess if the isolates were representative of viruses in vivo.   
 
Hypothesis:  Isolates are representative of viruses in vivo, with only minor changes 
represented in isolate env sequences as compared with env sequences derived from 
plasma viruses 
 
Approach:   Sequences of env genes from culture virus and env sequences derived from 
plasma viruses were compared to determine if HIV-1 env of the isolates was 
representative of viruses circulating in vivo for each participant, and determine if major 
changes were introduced during tissue culture.   
 
3) To determine whether differences in Env genotype exist between study arms by 
comparing env genotypic properties between TFV and PLB arms  
 
Hypothesis:  Viruses isolated from the TFV arm have more genotypic characteristics 
favouring transmission and infection, such as fewer glycosylation sites, shorter variable 
loops and are less charged.  In addition, TFV arm viruses are closer to a subtype C 
consensus of viruses circulating in vivo.  
 
Approach:   For each participant, the average number of glycosylation sites, variable loop 
length, and variable loop charge was compared between TFV and PLB arm isolates.  The 
predicted sites of glycosylation, loop length and charge were determined using online 
prediction tools.  In addition, a subtype C consensus env representing viruses circulating 
in the region was generated and the distance of isolate env sequences to the consensus 





4) To determine whether differences in Env function exist between study arms by 
comparing Env phenotypic properties between TFV and PLB arms including 
susceptibility to TFV, entry inhibitor sensitivities, and entry efficiency 
 
Hypothesis:  Viruses isolated from the TFV arm have more favourable phenotypic 
characteristics such as higher CD4 and CCR5 binding capacity, higher fusion capacity, and 
a lower CCR5 dependence. 
 
Approach:  Isolates were assessed in inhibition assays to evaluate Env sensitivity to entry 
inhibitors.  Maraviroc, T20, PSC-RANTES, and an anti-CD4 antibody, clone SK3 were the 
entry inhibitors chosen.  These inhibitors act at the level of CCR5 binding, fusion, and CD4 
binding, respectively.  In addition, Pseudoviruses (PSVs) were used in a virion-cell fusion 
assay to assess the entry efficiency of the isolates more directly.  Using this system we 
could assess the contribution of Env to viral fitness and compare this between different 
viruses without the confounding effects of functional differences in other viral proteins.   
 
5) To evaluate whether Env phenotypic characteristics of the isolates are 
associated with predictors of disease progression 
 
Hypothesis:  Participants infected with viruses that have higher CD4 and CCR5 binding 
capacity, higher fusion capacity, a lower CCR5 dependence, and higher entry efficiency 
will have a lower CD4 count at set-point and higher VLs. 
 
Approach:  Correlations of all phenotypic characteristics investigated (objective 4) with 
VL at isolation, 3 months post-infection and at set point, as well as CD4 count at set-point 
were performed. 
 
6) To compare the phenotypic characteristics of PSVs with the phenotypic 
characteristics of viral isolates.  
 
Approach: Inhibitor sensitivities to maraviroc, T20, PSC-RANTES and anti-CD4 antibody 
clone SK3 were compared between isolates and the PSVs generated using the majority 
env corresponding to the same participant.  These were evaluated to determine if 





The findings of this study may provide insight into entry characteristics of early viruses that result 






































2. Materials and Methods 
 
2.1 Ethics statement 
 
The CAPRISA 004 Microbicide trial was reviewed and approved by the University of KwaZulu-
Natal's Biomedical Research Ethics Committee (REC), Family Health International's Protection of 
Human Subjects Committee and the South African Medicines Control Council (95).  All 
participants of the study cohort provided informed consent for study participation.  This sub-
study, including laboratory protocols and the use of participant information, was reviewed and 
approved by the University of Cape Town’s (UCT) Faculty of Health Sciences Human REC (HREC 
REF number 587/2014). 
 
 
2.2 CAPRISA 004 participants and the TRAPS cohort 
 
The samples and information used in this study were from the Tenofovir gel Research for 
Advancing Prevention Science (TRAPS) programme, Durban, South Africa.  TRAPS was an 
ancillary study of CAPRISA004 where all consenting HIV-1 seroconverters were recruited, and 
followed up, as part of the CAPRISA 002 Acute Infection cohort.  Participants were followed until 
antiretroviral therapy commencement under the South African Antiretroviral Treatment 
Guidelines at the time; that is, when CD4+ T cell count fell below 350 cell/µL or at the presentation 
of AIDS-defining illness.  As part of the CAPRISA 004 trial protocol (95), blood samples (serum, 
plasma and PBMCs) were collected weekly for the first month, fortnight up to three months, 
monthly from months three to 12 and then at quarterly visits thereafter until antiretroviral 
therapy initiation.  VLs and CD4+ T cell counts measured at each sampling event, as well as gel 
adherence data, were provided.  In this study, VL at set-point was calculated as the average of 
three VL measurements around 12 months post-infection: the VL nearest the 12 month visit, and 
the measurements before, and after the 12 month visit.  VLs that differed by 1log10 were excluded 
from the average.  CD4 count at set-point was determined using measurements from the same 
visits used in the VL set-point determination for each participant.  
 
 
2.3 Sample selection for this study 
 
This study made use of blood plasma samples and clinical information obtained from 48 women 




Participants from the Tenofovir arm (n = 24) were matched to PLB arm controls (n = 24) based 
on the time post-infection that the plasma sample was obtained as well as protective human 
leukocyte antigens (HLAs) of the HIV-infected participant.  Adherence was measured by the 
number of unused applicators returned and the number of self-reported sex acts since the last 
study visit (data provided by N. Garrett).  TFV concentrations from cervicovaginal lavages were 
also measured as part of a previous study to determine whether participants had detectable levels 
of TFV in the vaginal mucosa (118). 
 
 
2.4 Cells and cell maintenance 
 
PBMC isolation 
Heparinized whole blood was obtained from HIV-negative donors and peripheral blood 
mononuclear cells (PBMCs) were isolated using Ficoll-Paque™ density gradient centrifugation.   
2mM ethylene-diamine-tetra-acetic-acid (EDTA) in phosphate buffered saline (EDTA-PBS) at pH 
7.2 was prepared and refrigerated at 4°C.  The PBS used in all protocols of this study did not 
contain any Calcium or Magnesium.  Whole blood was diluted four-fold in EDTA-PBS at room 
temperature.  35mL of diluted whole blood was layered carefully over 15mL Ficoll-Paque™ 
reagent in a 50mL conical tube which was then centrifuged for 20 min at 900 x g and at 20°C in a 
swinging bucket centrifuge without brake.  All centrifugation steps of this study were performed 
in an Eppendorf 5810R Centrifuge (Eppendorf, Hamburg, Germany) unless otherwise stated.  A 
10mL serological pipette was used to remove the mononuclear cell layer from the interphase of 
the Ficoll-Paque (bottom) and blood plasma (top) layers; being careful not to disturb the layers.  
This was transferred to a fresh 50mL tube, made up to 50mL with EDTA-PBS and centrifuged for 
10 min at 900 x g at 20°C.  In order to remove platelets from the mononuclear cells, the pellet was 
resuspended in 50mL EDTA-PBS and centrifuged for another 10 min at 900 x g after which the 
supernatant (containing platelets) was removed.  This wash step was repeated to ensure removal 
of all platelets.  Cells were diluted two-fold in Trypan Blue (Invitrogen, CA, USA) to a total volume 
of 20µL and subsequently counted using a Countess cell counter and counting chamber slides 
(both by Invitrogen).   
 
CD8+ T cell depletion of PBMCs & cell storage 
CD8+ T cells were depleted from unstimulated PBMCs to ensure that HIV replication was not 
inhibited by these cells during virus isolation (152).  This was achieved by magnetic labelling of 
CD8+ T cells using MACS CD8 MicroBeads (all MACS products were from Miltenyi Biotec, CA, USA) 




DPBS were centrifuged (300 x g for 10 min at 20°C) and the pellet was resuspended in 80 µl MACS 
buffer + 20 µl CD8 MicroBeads per 1 x 107 cells after removal of the supernatant.  This was mixed 
well and the suspension was incubated for 15 min at 4°C.  Cold wash buffer was prepared by 
diluting bovine serum albumin (BSA) in EDTA-PBS to a final concentration of 0.5%v/v.  A MACS 
magnetic column was placed in the magnetic field of a MACS Separator mounted on a MACS 
MultiStand.  The columns were prepared by rinsing twice with 2mL volumes of buffer.  The 
labelled PBMCs were then added to the columns which were subsequently washed three times 
with 3mL of buffer each time.  Any CD8+ cells were retained in the column.  The cells in the effluent 
(desired cells) were counted using the Countess cell counter as described previously.  Cells were 
pelleted by centrifugation (500 x g for 10 min) and resuspended to a final concentration between 
2 x 107 and 5 x 107 cells/mL in foetal bovine serum (FBS) containing 10% dimethyl sulfoxide 
(DMSO).  PBMCs were frozen in 1mL aliquots at -80°C for one hour in a freezing container to 
ensure a 1°C/min decrease in temperature and then placed in liquid nitrogen (-196°C) for long-
term storage until needed. 
 
Cell lines 
The HEK293T cell line was obtained from the American Type Culture Collection (ATCC® 
CRL3216™) and is a human embryonic kidney cell line used for the production of proteins by 
transfection with plasmid DNA (153, 154).  The TZM-bl cell line was obtained through the 
National Institute of Health (NIH) AIDS Reagent Program- Division of AIDS, NIAID, NIH from Dr 
John C.  Kappes, Dr Xiaoyun Wu and Tranzyme Inc (155–159).  It is a HeLa cell line expressing 
CD4 and CCR5 which allows for entry of HIV virions into the cell.  The cells also have a firefly 
luciferase reporter gene under the control of the HIV-1 long terminal repeat (LTR).  The viral Tat 
protein binds to the LTR to initiate transcription of viral proteins during the normal viral 
replication cycle.  Hence, viral entry, reverse transcription, integration and expression of the viral 
Tat protein results in expression of the luciferase reporter.  This reporter system allows for 
quantification of infectivity of viral isolates by measuring luminescence after the addition of a 
luciferase detection reagent (SteadyLite, Perkin Elmer, MA, USA) to the infected cells.  SteadyLite 
reagent lyses the cells and contains D luciferin, the substrate acted on by firefly luciferase 







Figure 2.1.  A schematic showing the SteadyLite reaction.  Figure taken from the SteadyLite 




Both cell lines were maintained in D10F growth medium (GM) which consists of Dulbecco’s 
Modified Eagle Medium (DMEM) containing phenol red and supplemented with 50 µg/mL of 
gentamicin as well as 10% FBS.  All cell culture incubation steps in this study were carried out in 
a humidified incubator at 37°C.  Cells were grown in monolayers in T75 filter cap tissue culture 
flasks and were passaged every 2 to 4 days when they reached 70% to 80% confluency.   
 
Passaging of HEK293T cells was carried out as follows: medium was removed and cells were 
washed with 5mL Dulbecco’s Phosphate-Buffered Saline (DPBS) without Calcium or Magnesium 
to remove trypsin inhibitors.  Thereafter, 5mL pre-warmed (37°C) 1X trypsin-EDTA (0.25% 
trypsin, 1mM EDTA) solution was added to the cells in order to cleave proteins that support cell 
adherence to the flask.  Cells were incubated for one minute at room temperature after which 
5mL pre-warmed D10F GM was used to inactivate the trypsin solution and wash the cells off the 
bottom of the flask.  The cell suspension was transferred to a 15mL conical tube, centrifuged for 
5 min at 900 x g and the pellet resuspended in 10mL D10F GM for counting.  Cell counting was 
performed as described previously for PBMCs.  Each new flask was seeded with 0.5 x 106 to 2 x 
106 cells.  TZM-bl cells were passaged in a similar manner with the following exceptions:  
i. TZM-bl cells were incubated with 7 mL trypsin solution for up to five min at 37°C; 






2.5 Isolation of early viruses 
 
PBMC stimulation 
To minimize the effect of differences in donor PBMC susceptibility to HIV-1 infection on the 
efficiency of virus isolation (160), a 3x3 stimulation protocol was employed where PBMCs 
obtained from three different donors were stimulated under three different conditions (161, 132) 
to obtain a mix of PBMCs each time cells were added.  Cell culture flasks were coated with OKT3 
(BioLegend, CA, USA), which is an anti-CD3 monoclonal antibody, 24h before PBMC stimulation.  
OKT3 was diluted to a concentration of 10 µg/mL in DPBS and added to the flask which was 
incubated horizontally in a 37°C humidified incubator overnight.  The total volume of OKT3-DPBS 
required to coat a T25 or T75 flask was 5mL or 10mL, respectively.  Thereafter, the OKT3-DPBS 
was removed from the flask.  CD8+ depleted PBMCs from three buffy coat donors were thawed 
rapidly in a water bath set to 37°C.  These were pooled, mixed well and diluted in RPMI 1640 
supplemented with 10% FBS, 50 µg/mL gentamicin, 2mM L-glutamine and 200 U/mL IL-2 (IL-
2/stimulation medium) to a concentration of 4 x 106 cells/mL.  The pooled cells were split into 
three equal fractions; the first of which was added to the OKT3-coated flask.  The remaining two 
fractions were added to two fresh flasks which were subsequently supplemented with 
phytohemagglutinin (PHA) to final concentrations of 0.5 µg/mL and 5 µg/mL, respectively (132, 
161, 162).  All three flasks were incubated in a humidified incubator for 72h; the PHA flasks 
incubated vertically and the OKT3 flask incubated horizontally.  Over the incubation period 
roughly 50% of cells die; therefore, this was accounted for when determining the total number of 
PBMCs to stimulate prior to each application.   
 
Virus isolation from plasma & infection of PBMCs 
Viruses were isolated from participant plasma using the µMACS VitalVirus HIV Isolation Kit 
(Miltenyi Biotec).  The principle involves positive selection of HIV by magnetically labelling 
virions which contain CD44, a mammalian cell surface marker, in their lipid envelopes (163).  
Subsequent addition of the magnetically labelled sample to a magnetic column captured the 
labelled viruses, which were later eluted from the column, while the remainder of the sample 
flowed through the column.  Frozen plasma samples were thawed rapidly in a 37°C water bath 
and immediately centrifuged at 13 000 x g for 30s to remove large particles and cell debris.  One 
millilitre of plasma (supernatant) was incubated with 250µL CD44 magnetic MicroBeads in a 
fresh tube at room temperature for 30 min.  During incubation, PBMCs stimulated under the three 
different conditions described above, were pooled and counted as described previously using a 
Countess cell counter.  The stimulated PBMCs were centrifuged at 900 x g for 10 min at room 




cells/mL.  Cells were seeded at 0.7 x 106 cells per well in a 24-well plate (100 µL cell suspension 
per well).  One µColumn per plasma sample was placed in the magnetic field of a µMACS Separator 
mounted on a MACS MultiStand.  The column was prepared by adding 100 µL of equilibration 
buffer to the column followed by three washes with 100µL of virus wash buffer supplemented 
with 2% FBS.  The magnetically labelled sample was then added to the column followed by four 
200µL washes with the virus wash buffer.  After removal of the columns from the magnetic 
separator, magnetically labelled virus was eluted directly into a single well of the 24-well plate 
using 350µL IL-2 medium and a syringe plunger.  Plates were spinoculated for 60min at 1200 x g 
and at 25°C.  Thereafter, plates were mixed gently and placed in a humidified 37°C incubator 
overnight.   
 
Expansion & maintenance of infected cultures 
The following day, 550µL fresh, pre-warmed IL-2 medium was added to each well up to a total of 
1ml and the plates were placed back into the incubator.  This was repeated 72h later at (day three) 
with 1mL IL-2 medium.  On day seven, cultures were transferred to 6-well plates containing 2 x 
106 stimulated PBMCs per well in 2mL medium; adding up to a final volume of 4mL.  On day ten, 
these cultures were centrifuged at 900 x g and the resuspended in 10mL fresh, pre-warmed IL-2 
medium and transferred to T25 culture flasks incubated vertically in a 37°C humidified incubator.  
Virus cultures were assayed for virus production by Gag p24 ELISA every seven days (see method 
described in section 2.6).  On day 14, the infected PBMCs from intermediate and highly positive 
cultures were resuspended in 10mL fresh Il-2 medium and added to T75 culture flasks containing 
either 4- or 8 x 106 freshly stimulated PBMCs in 4 and 8mL IL-2 medium, respectively.  PBMCs 
from Gag p24-negative cultures were resuspended in 10mL fresh Il-2 medium and transferred to 
T75 culture flasks containing 1 x 106 freshly stimulated PBMCs in 1mL IL-2 medium.  Cultures 
were maintained in this way for 25-52 days with medium being refreshed as described every 
three days and cells being replenished as described every seven days. 
 
Harvesting & storage of virus stocks 
From day 18 onwards culture supernatants were harvested every three days and stored in 50mL 
conical tubes at -80°C.  Aliquots of each culture were stored separately in order to perform p24 
ELISAs as well as titration experiments in TZM-bl cells (see method described in section 2.7) after 
a single freeze-thaw cycle with all harvest days in the same experiment.  The results of the p24 
determination and viral titres were compared for all harvested supernatants and the harvest 
which had the highest titre in TZM-bl cells was thawed in a 37°C water bath and placed in long-





2.6 Quantification of p24 antigen in viral isolate stocks 
 
In-house ELISA 
The Gag p24 content in viral culture supernatants was checked at regular intervals by enzyme-
linked immunosorbent assay (ELISA).  The protocol was developed in the Williamson laboratory 
(P. Selhorst, University of Cape Town, South Africa) and is based on a sandwich ELISA principle 
(fig.  2.2) in which a 96-well plate is coated with an anti-p24 capture antibody that will bind p24 
antigen in the sample.   
 
 
     
 
Figure 2.2.   The sandwich ELISA principle used for quantifying the amount of p24 antigen in a 
sample.  The figure depicts a single reaction taking place in a single well of a 96-well microtiter 
plate to which the coating antibody is bound with high affinity.  In reality the entire surface of the 
well is covered with coating antibodies. 
 
 
After washing, only the coating antibody and the bound p24 remain.  Thereafter, a secondary anti-
p24 antibody which is conjugated to alkaline phosphatase is added to the well and binds the p24 
at a different epitope to the first antibody.  After addition of the chemiluminescent substrate, 





Figure 2.3.  A schematic showing the action of alkaline phosphatase on the chemiluminescent 
substrate, Tropix® CDP-Star with Sapphire-II™.  Figure taken from the Applied Biosystems 





Briefly, high-bind 96-well white, opaque microtiter plates (Corning® COSTAR®, NY, USA) were 
coated with 100 µL anti-HIV-1-Gag p24 antibody D7320 (sheep anti-HIV monoclonal) (Aalto Bio 
Reagents, Dublin, Ireland) which was diluted 1:600 in sodium bicarbonate (0.1M, pH 8.5) from 
stock concentration of 2mg/mL prior to coating.  Plates were incubated overnight at room 
temperature and then washed 3 times with 1X TBS buffer (Appendix 1).  The plates were then left 
to dry for 2h and stored at -20°C until needed.   
 
Dilutions of culture supernatant were made for each culture; starting with neat supernatant.  A 
20 µL volume of a 5% solution of Empigen (Sigma-Aldrich, MO, USA) was pipetted into each well 
of the plate to which 80µL of viral culture supernatant was directly added in order to lyse virions 
and release p24.  The p24 antigen standard was prepared by diluting recombinant HIV-1 Gag p24 
(Aalto Bio Reagents) to a starting concentration of 12.5 ng/mL in cell culture medium.  Thereafter, 
seven two-fold serial dilutions were made by diluting the p24 standard in the appropriate cell 
culture medium (the same one as in the samples).  The Gag p24-standard dilutions were applied 
to the ELISA plate in duplicate with the eighth well in the dilution series containing cell culture 




then washed three times with 400µL of 1X TBS buffer.  The secondary conjugate antibody (mouse 
anti-HIV monoclonal), alkaline phosphatase conjugate BC1071-AP (Aalto Bio Reagents), was 
diluted 1:12500 in 1X TBS containing 0.1% Tween-20 (Sigma-Aldrich) and 100 µL was applied to 
each well of the ELISA plate after the first wash.  This was incubated for 1h at room temperature 
and then washed four times with 400µL of 1xTROPIX-0.1% Tween buffer  CDP Star® substrate 
with Sapphire-II™ (Novex®, Life Technologies, CA, USA) was diluted 1:10 in 1X TROPIX buffer and 
100 µL was added to each well of the ELISA plate after the second wash.  After exactly 30 min 
incubation period with plates covered to ensure no exposure to light, luminometer readings were 
obtained (GLOMAX® 96-Mcroplate Luminometer using the Promega BrightGlo Protocol; 
Promega, WI, USA) as relative light units (RLU).  The in-house ELISA was used in order to narrow 
down the dilution range required to quantify the amount of p24 and reduce the cost of performing 
the assay using a commercial ELISA kit, which provided more accurate p24 quantitation.  
 
Commercial ELISA 
The Gag p24 antigen content of each viral stock was confirmed by the commercially available 
PerkinElmer Alliance ELISA Kit (PerkinElmer) using the cell culture supernatant protocol.  This 
kit provided accurate p24 quantification with reduced variation between experiments.  The 
protocol follows a sandwich ELSA principle as described above.  Briefly, the microplates were 
supplied pre-coated with a mouse monoclonal anti-p24 capture antibody which binds Gag p24 
antigen.  A viral lysis reagent (Triton X-100) was added to each well of a microplate.  Dilutions of 
the virus stocks were added to each well and the plates were incubated at 37°C for 2h.  Thereafter, 
plates were washed six times with the wash buffer supplied and a biotinylated polyclonal anti-
HIV-1 p24 antibody was added to each of the sample wells.  The plates were then incubated at 
37°C for another hour and then washed six times with the same wash buffer.  A Streptavidin-
horseradish peroxidase (HRP) conjugate was added to the plate which was incubated at room 
temperature for 30 min.  After a final six-wash step, ortho-phenyl-diamine-HCl (OPD) substrate 
was added to all wells and the plates were incubated at room temperature for 30 min in the dark.   
 
OPD cleaved by HRP produces a yellow colour and the production of colour is directly 
proportional to the amount of p24 captured in each well.  A stop solution was added after the final 
incubation period.  Colour output was measured at 650nm and 490nm using an absorbance 
reader blanked on air.  All plates were read within 15 min of stopping the reaction.  In addition to 
sample dilution-containing wells, each plate had a substrate blank well and a standard curve 
loaded in duplicate.  The substrate blank well did not undergo addition of lysis agent, sample or 




The standard curve was produced using the purified HIV-1 p24 supplied with the kit which was 
diluted to a 100pg/mL starting dilution and then serially diluted seven times by a factor of two.   
 
 
2.7 Titration of isolate stocks  
 
The relative titre for each stock of viral isolates was determined using a 50% Tissue Culture 
Infectious Dose (TCID50) assay.  The assay is based on infection of TZM-bl cells at various dilutions 
of virus stock to ascertain the concentration at which 50% of replicate wells result in ‘positive’ 
detection of infection.  Infection is measured by luminescence after the addition of a firefly 
luciferase substrate to the cells.  TZM-bl cells were seeded in a 96-well tissue culture-treated 
microtiter plate at a density of 1 x 104 cells per well in a final volume of 100µL of D10F GM with 
DEAE-dextran added at a final concentration of 40 ug/mL.  DEAE-dextran is a polycation that 
increases cell-free virus infection by stabilizing virion adsorption to the cell membrane allowing 
for enhanced viral entry (164).  Three-fold serial dilutions of the isolate stocks were made and 
100µL of each dilution was to six replicate wells.  Six background control wells were included per 
plate; by adding 100µL D10F GM instead of virus dilution to the cells.  Outer wells of the plate 
were filled with 200 µL sterile water to decrease evaporation.  After a 48h incubation period at 
37°C, 120 µL of supernatant was removed from each well and replaced with 75µL SteadyLite 
reagent (PerkinElmer).  Plates were incubated for 10 minutes at room temperature in the dark.  
The contents of each well were mixed and 100µL was transferred to an opaque white 96-well 
microtiter plate.  Luminometer readings were obtained as described in section 2.6.  Wells with 
RLUs greater than 2.5 times the average background value (average RLU from all negative control 
wells) were considered positive.  Viral titres were calculated using the Reed and Muench method 
(165) and expressed as infectious units per mL. 
 
 
2.8 Amplification and sequencing of viral envelope genes 
 
RNA extraction & cDNA synthesis 
One 500µL aliquot of each culture supernatant was thawed in a 37°C water bath and a 1:100 
dilution in DPBS was made for each.  HIV-1 RNA extractions were carried out on 200µL of the 
diluted supernatant using the Roche MagNA Pure Compact System and Roche MagNA Pure 
Compact RNA Isolation kit (Roche, Basel, Switzerland).  RNA was eluted in 50µL final volume of 
elution buffer; 25µL of which was reverse transcribed into cDNA on the same day to avoid 




carried out using a SuperScript™ III Reverse Transcriptase (RT) System (Invitrogen) with 
oligo(dT) as a primer.  The final concentration of reagents in each reaction were as follows: 
0.4mM dNTPs, 2µM oligo(dT), 1X Superscript buffer, 5mM DTT, 2 Units (U)/µL RNAseOUT 
(Ribonuclease inhibitor), 10U/µL SuperScript III™ reverse transcriptase and ddH2O to a final 
volume of 50µL.  These were set up as two separate master mixes.  The RNA along with the dNTPs 
and oligo(dT), the first master mix, were added to 0.2mL PCR tubes and placed on a heating block 
set to 65°C for 5 min.  Thereafter, the mix was put on ice for 1 min and the remainder of the 
reagents, in a second master mix, were added to each tube.  The reaction was run on a 
thermocycler at 45°C for 2h and then 75°C for 15min to inactivate the RT enzyme.  Thereafter, 2U 
RNAseH was added to each tube after which tubes were incubated for another 20 min at 37°C to 
digest the RNA template.  cDNA was stored at -80°C until needed. 
 
Single genome amplification (SGA) & sequencing 
cDNA was thawed and serially diluted in molecular grade water (Sigma-Aldrich) in order to 
obtain less than 50% positive amplification reactions at which, theoretically, each positive 
reaction would have been amplified from a single copy of HIV-1 cDNA 69% of the time (166).  
Where possible, this was decreased to less than 30% positive in which case each reaction would 
have been amplified from a single cDNA copy more than 80% of the time.  The SGA method was 
adapted by Salazar-Gonzalez et al.  in order to reduce recombination and Tat-induced error when 
amplifying env from HIV-1 cDNA (27, 151).  For amplification of env, a nested PCR was performed 
in which two rounds of PCR yield the desired product; the second round primers being nested 
within the first.  Briefly, 1µL cDNA of a particular dilution was added to eight replicate wells of a 
96-well PCR plate for first-round synthesis using OFM19 (5’-
GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’) and VIF1 (5’-GGGTTTATTACAGGGACAGCAGAG-3’) 
forward and reverse primers.  Similarly, 1µL of first-round PCR product was added to 
corresponding wells of a second 96-well PCR plate for synthesis of the final product using EnvA 
(5’-GGCTTAGGCATCTCCTATGGCAGGAAGAA-3’) and EnvN (5’-
CTGCCAATCAGGGAAGTAGCCTTGTGT-3’) forward and reverse primers.  The concentrations of 
reagents (Invitrogen) in each reaction were as follows: 1X High Fidelity Buffer, 2mM magnesium 
sulfate (MgSO4), 0.2mM of each dNTP, 0.2µM of each primer, 0.025 U/µL Platinum® Taq DNA 
Polymerase High Fidelity enzyme and ddH2O to a final volume of 19µL.  The first round PCR was 
carried out under the following cycling conditions: 94°C for 2 min, then 35 cycles of 94°C for 15s, 
55°C for 30s and 68°C for 4min, followed by a final elongation at 68°C for 20min.  The second 
round PCR was performed under the same conditions but for 45 cycles.  Post-PCR clean-up and 
sequencing of the second-round product was carried out through the Central Analytical Facilities 




USA) and BigDye terminator reagents.  Twelve gp160 primers (Appendix 2) spanning the length 




Sequences for each env gene for each participant were compiled using Sequencher (v5.2.4) and 
aligned and visualized using BioEdit (v7.1.11) and AliView (v1.18) (167).  MACSE (168) was used 
for all codon alignment.  Sequences containing more than three ‘double peaks’ in the 
chromatogram, indicating the presence of more than one template during the amplification, were 
excluded.  Those with one or two ‘double peaks’ were included.  env sequences were compared 
to SGAs from plasma and derived transmitted/founder env sequences generated internally (Z.  
Valley-Omar, C.  Rademeyer, R.  Thebus & M.  Logan, personal communication).  Those SGAs 
generated in this study with deletions larger than 50 nucleotides compared with the plasma 
consensus were also excluded.  Differences in both nucleotide and translated (using BioEdit) 
amino acid sequences were visualized using the Highlighter tool on the Los Alamos website 
(www.hiv.lanl.gov) as well as by neighbor-joining trees compiles using MEGA 6 (169).  Pairwise 
DNA and amino acid distances between sequences were computed using MEGA 6.  For this 
comparison, a consensus was generated using sequences from CAPRISA 002 participants who 
were recruited from the same population and same geographical region as CAPRISA 004 
participants.  A total of 592 env SGAs were aligned in MACSE and used to generate a consensus 
sequence in BioEdit. Variable loop length, charge and glycosylation prediction was performed 
using the Variable Region Characteristics tool and NX[ST] glycosylation sites were visualized 
along the env sequence with the N-glycosite tool (170), both on the Los Alamos website.  For those 
infections that were not previously classified as single or multivariant transmissions, full-length 
plasma env sequences were used to predict multiplicity of infection using the Poisson-fitter tool 
(171) on the Los Alamos website, the phylogenetic trees, and highlighter plots generated. 
 
 
2.9 Cloning of isolate envelope genes 
 
An env SGA which was representative of the majority variant identified in the screened isolate 
sequences was selected for cloning.  Where only one isolate sequence was obtained, that variant 
was cloned.  Where two isolate sequences were obtained for the participant, the sequence which 
had the fewest number of nucleotide changes to the derived transmitted/founder sequence of the 
plasma sequences was selected for cloning.  Second-round bulk amplification of the selected first 




identical to the second round amplification described in section 2.8; however, a different forward 
primer was used to introduce the 5’ CACC tag required for directional cloning; that is, EnvA-Rx 
(5'-CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3').  The four replicate reactions were pooled 
and purified using the Qiagen MinElute PCR Purification kit (Qiagen, Venlo, Netherlands).  The 
size and integrity of the resultant product was confirmed as ~3kb by gel electrophoresis through 
a 1% agarose gel.  The following was mixed and loaded into each well: 2µL PCR product added to 
1µL 6X loading dye containing GelRed and 3µL ddH2O.  Bands were visualized with the UVIpro 
Silver gel documentation system (UVItec, Cambridge, UK).  The amount of DNA in the purified 
PCR product was quantified using a NanoDrop 2000 (Thermo Scientific, MA, USA) in order to 
determine the volume required for the cloning reaction. 
 
The pcDNA™3.1 Directional TOPO® Expression Kit (Invitrogen) was used for directional cloning 
of env genes.  The system uses a topoisomerase-linked linearized mammalian expression vector.  
The topoisomerase binds to the 5’-CACC-3’ tag sequence introduced on the 5’ end of env amplicon 
to ligate it into the plasmid.  The gene of interest is inserted downstream of a cytomegalovirus 
(CMV) promoter which ensures constitutive expression of the gene at high levels in mammalian 
cells.  Each cloning reaction was set up in a 0.2mL tube with reagents as follows:  10ng of the 
desired env PCR product in a volume of 0.5 to 4µL, 1µL salt solution, 1µL TOPO® vector and sterile 
ddH2O to a final volume of 6µL.  This was mixed gently and incubated at room temperature for 20 
min and then placed on ice.   
 
Next, one Shot® Stbl3™ chemically competent E.  coli cells (Invitrogen) were thawed on ice and 
transformed with the obtained env plasmids.  Briefly, 5µL of each TOPO® cloning reaction was 
added to the cells, mixed gently and incubated on ice for 30 min.  The transformation reactions 
were then heat shocked in a 42°C water bath for 30s without shaking and transferred to ice for 
2min.  Thereafter, 250µL Luria-Bertani medium (appendix 1) was added to each vial of cells.  The 
vials were placed in a shaking incubator (225 rpm) for 1 hour at 37°C.  After incubation, 200µL of 
each bacterial culture was spread onto a pre-warmed LB agar plate (Appendix 1) containing 100 
mg/mL carbenicillin (Sigma-Aldrich) for positive selection of transformants.  The plates were 
incubated at room temperature until the appearance of colonies two- to three days later.   
 
At least eight colonies per cloning reaction were screened by colony PCR to confirm whether the 
desired insert was present.  Colony PCR was performed in a 96-well plate format using the T7 
forward (5’-TAATACGACTCACTATAGGG-3’) and Rev 15 reverse (5’-
ACTTTTTGACCACTTGCCACCCAT-3’) primers.  The final concentrations of reagents in each 




dNTPs, 0.3 µM of each primer and 0.015 U/µL SuperTherm Taq DNA polymerase.  Cycling 
conditions were as follows: 94°C for 3 min, then 35 cycles of 94°C for 15s, 55°C for 45s and 72°C 
for 2.5 min, and a final elongation step of 72°C for 7min.  After 1% agarose gel electrophoresis as 
previously described, colonies that were identified as having the desired insert were used to 
inoculate 5mL LB broth containing 100 mg/mL carbenicillin which was incubated overnight 
(<16h) in a 32°C shaking incubator at 225 rpm.  Bacteria from 4mL of the overnight cultures were 
pelleted at 9600 x g in a Heraeus™ Pico™ 21 microcentrifuge (Thermo Scientific) for 3 min at room 
temperature.  After removal of all medium from the pellet, plasmid DNA was extracted using a 
QIAprep Spin Miniprep Kit (Qiagen).  DNA was eluted in 50µL final volume of sterile ddH2O and 
quantified using a NanoDrop 2000.  The remaining 1mL bacterial culture was added to 1mL 
sterile glycerol to obtain 50% glycerol stocks which were stored at -60°C. 
 
 
2.10  Generation of pseudovirus stocks 
 
In order to identify whether clones were functional, a small-scale test for function was carried out 
in 96-well microtiter plates.  PSVs were produced by co-transfection of HEK293T cells with an 
env clone and a plasmid containing an HIV-1 subtype B genome which has an env deletion, 
pSG3Δenv, as previously described (158, 172).  In this way all PSVs produced had the same proteins 
except for Env which was participant-specific.  The pSG3Δenv reagent was obtained through the 
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Drs.  John C.  Kappes and Xiaoyun 
Wu (158, 172).  HEK293T cells were seeded at 2 x 104 cells/well into a 96-well round-bottom 
plate in a final volume of 100µL D10F GM.  For each clone, 0.15µg plasmid DNA was added to 
0.3µg pSG3Δenv backbone DNA and the volume adjusted to 15µL with sterile ddH2O.  PolyFect 
transfection reagent (2mg/mL, QIAGEN) was diluted in DMEM and 50µL added to each plasmid 
DNA mix such that the mass ratio of Env plasmid DNA:backbone-DNA:PolyFect was 1:2:26 (in this 
case 4µg per transfection).  This was mixed by vortexing for 5s and then incubated at room 
temperature for 15 min.  Each mix was subsequently added directly to the wells containing 
HEK293T cells up to a total well volume of 165µL.  This was incubated for 48h in a 37°C 
humidified incubator. 
 
Next, TZM-bl cells were seeded at a density of 1 x 104 cells per well in a final volume of 100 µL of 
GM with DEAE-dextran added at a concentration of 40 µg/mL.  50µL Pseudovirus-containing 
supernatant from the transfection plates was added directly to wells containing cells and DEAE-
dextran in duplicate to a final volume of 150µL.  After 48h incubation, the supernatant was 





Functional clones were sequenced as described in section 2.8 and the clone with the fewest 
number of non-synonymous substitutions from the sequence selected for cloning was chosen to 
produce large-scale stocks for PSVs.  HEK293T cells were seeded at a density of 3 x 106 cells per 
T75 flask in 10mL D10F and incubated overnight in a 37°C humidified incubator.  The next day, 
pSG3Δenv backbone and env clones were mixed and incubated as described previously using 8µg 
of backbone plasmid, 4µg of env-containing plasmid and 120 µg of PolyFect reagent (mass ratio 
of 1:2:30) per transfection in a final volume of 650µL of D10F.  During incubation of the DNA with 
the PolyFect, the medium in each T75 flask containing cells was replaced with 15mL fresh D10F 
after which the DNA-PolyFect mix was added to the flasks.  After 48h incubation, the supernatant 
was removed, aliquoted and stored at -80°C.  This was replaced with 7mL fresh medium which 
was removed and stored as aliquots 24h later to obtain a second harvest.  Determination of Gag 
p24 concentrations in each stock of PSVs was determined as described previously by both in-
house and commercial ELISA.  PSVs from the first harvest were used for all assays that followed.   
 
 
2.11  Entry efficiency assays 
 
Entry efficiency assays were performed as described for titration experiments above with the 
difference being that no DEAE-dextran was added to the experiments.  Briefly, TZM-bl cells were 
seeded at a density of 1 x 104 cells per well in a final volume of 100µL of GM without DEAE-
dextran.  Three-fold dilutions of PSV stocks were made by diluting neat stocks in D10F GM.  100µL 
of neat supernatant and dilutions were then added to the individual wells in triplicate to a final 
volume of 200µL per well.  After 48h incubation, the SteadyLite protocol which was described 
earlier was carried out.  RLU measurements for each PSV were normalized on the p24 input 
(commercial ELISA) in each well to obtain entry efficiency measurements.  Average RLU/pg p24, 
which was used as a measure of entry efficiency, was calculated across all replicate wells for a 
particular virus incorporating all dilutions within the linear range for each plate.   
 
 
2.12  Inhibition assays using isolates and pseudoviruses  
 
TZM-bl cells were seeded in a 96-well tissue culture-treated microtiter plate at a density of 1 x 
104 cells per well in a final volume of 100µL of D10F GM with DEAE-dextran added to a final 
concentration of 40 µg/mL.  Five-fold serial dilutions of various inhibitors were made.  The 




inhibitor), tenofovir (nucleotide reverse transcriptase inhibitor), JM-2987 (CXCR4 inhibitor), 
PSC-RANTES (CCR5 competitive inhibitor) and SK3 (monoclonal anti-CD4 antibody).  50µL of 
each dilution of inhibitor was added to wells in duplicate and plates were incubated at room 
temperature for 30 min.  Thereafter, virus (or PSV) dilutions were added to wells such that the 
multiplicity of infection in each well was 200 TCID50.  Microtiter plates were incubated for 48h 
after which 120µL of supernatant was removed from each well and replaced with 75 µL 
SteadyLite.  After 5 min incubation at room temperature in the dark, the contents of each well 
was mixed by pipette action and transferred to an opaque white 96-well microtiter plate.  
Luminometer readings were obtained as described in section 2.5.  Antiviral activity was 
expressed as the percentage of viral inhibition in experiment wells compared to untreated 
controls wells and subsequently plotted against the compound concentration.  Nonlinear 
regression analysis was used to calculate the EC50 based on at least three independent 
measurements.  Regression analysis was performed using GraphPad Prism software, version 
5.03, for Windows (GraphPad Software, CA, USA). 
 
 
2.13  Statistical analysis 
 
All P-values were calculated using STATA (Special Edition 11.0).  Graphs were generated using 
GraphPad Prism.  The Shapiro-Wilk test for normality was applied to each data set as well as a 
test for equal variances prior to calculation of the P-values.  For all comparisons where the data 
was normally distributed, the P-values were calculated using a two-sample t-test.  Where the data 
was not normally distributed, or had unequal variances despite being normally distributed, a non-
parametric test was employed as with cases where the sample size in each group was <30.  Where 
multiple comparisons were made, the P-value cut-offs were adjusted using a Bonferroni 
correction.  Where a parametric test was employed, the 95% confidence interval (CI) was 
reported in the results.  Where a non-parametric test was used, the interquartile range (IQR) was 
reported.  Due to the small sample size all correlations were performed using a Spearman 













3.1 Cohort and isolate  description 
 
This study characterized HIV-1 from participants who seroconverted while participating in the 
CAPRISA 004 1% TFV microbicide study, and who were enrolled into the CAPRISA 002 acute 
infection cohort.  To capture features associated with the virus that founded clinical infection 
(transmitted/founder or T/F), only participants who were enrolled within 3 months of estimated 
date of infection were included.   Participants assigned to TFV gel use (n= 24) were matched with 
PLB user controls (n=24) according to time post-infection, as well as the presence or absence of 
protective HLAs in both individuals of each pair.  Due to the relatively small number of 
participants who seroconverted while enrolled in the CAPRISA 004 trial, participants could not 
be matched according to HLA type.  Appendix 3A gives a description of the 24 matched pairs.   
 
Of the 48 participants selected, viruses from 39 participants were successfully isolated on PBMCs 
(81%).  Genotypic characterisation of env was performed to determine if these viruses were a 
good representation of viruses circulating in vivo (see section 3.2).  A subset of 28 viruses (14 
pairs; table 3.1) was selected for inhibition assays to evaluate whether phenotypic differences 
exist between viruses from the TFV and PLB arms, and whether characteristics correlate with 
predictors of disease progression in this study population.  The subset was selected based on 
detectable levels of TFV in plasma samples taken at the study visit closest to the estimated date 
of infection.  Of this subset, envs from 20 participants were cloned and entry efficiency was 
determined.  For the 39 viruses isolated, VL at time of isolation did not differ between trial arms 
(P= 0.2567; Wilcoxon rank sum test for independent samples) with a median VL of 5.06 and 4.78 



































CAP320 37 500 30 550 1 607 5 Yes CAP345** 130 000 271 500 222 000 6 No 
CAP325* 127 000 66 350 10 261 3 No CAP327* 91 600 250 500 224 579 3 No 
CAP343 130 000 47 200 35 748 7 Yes CAP317 351 000 534 000 682 000 7 No 
CAP360 80 600 11 460 8 628 3 Yes CAP301 33 500 3 670 <400 4 Yes 
CAP363* 97 500 96 050 4 617 5 No CAP292* 458 000 43 733 256 085 5 No 
CAP367 3 360 000 428 500 142 970 3 No CAP326 31 500 16 300 4 329 3 No 
CAP283** 12 900 14 300 74 445 7 No CAP306 141 000 38 900 19 530 8 Yes 
CAP291 14 300 12 000 2 507 11 No CAP349 950 000 732 000 429 247 11 No 
CAP318 22 300 25 700 46 632 5 No CAP307 174 000 107 000 147 459 5 No 
CAP323 22 000 2 193 3 044 3 Yes CAP315** 108 000 65 400 793 3 Yes 
CAP334 21 200 3 150 8 077 6 Yes CAP311 18 600 1 390 855 6 No 
CAP348 305 000 112 267 21 581 8 Yes CAP287 13 200 52 000 9 174 8 No 
CAP370 28 800 8 570 12 237 5 Yes CAP331 12 700 1 550 8 574 6 No 
CAP375 192 000 110 900 20 117 5 Yes CAP357** 14 900 7 765 22 588 7 No 
VL reported as copies/mL 
Ɨ VL in the plasma sample from which viruses were isolated  
ǂ TFV detected in plasma at the time-point used for virus isolation  
ɸ Protective HLAs present or absent in both participants of the TFV-PLB pair 




VL set-point was defined as the geometric mean of HIV-1 plasma VL measurements from three 
consecutive study visits around 12 months post-infection in ART-naïve participants (the visit 
closest to 12 months post-infection as well as one visit preceding and one immediately following 
the 12-month visit).  In participants who initiated ART before 12 months post-infection, set-point 
was defined as the last available VL measurement before ART initiation.  ART was initiated 
according to National Treatment Guidelines at the time; which was a CD4+ count of <350 cells/µL.  
Two participants initiated ART prior to 12 months: CAP317 (PLB arm) and CAP375 (TFV arm) 
initiated ART at 6.3 months and 8.5 months post-infection, respectively.  In the subset of 28 
viruses selected for viral inhibition assays, VL at isolation, 3 months post-infection and set-point 
did not differ significantly between trial arms (P= 0.7304, 0.6133 and 0.4082, respectively; 
Wilcoxon rank sum test for independent samples). 
 
 
3.2 Isolates are genotypically representative of plasma viruses  
 
In order to demonstrate that isolates were representative of plasma viruses, the env gene isolate 
sequences were compared to sequences generated from plasma at the same time-point post-
infection for 34 of the 39 isolates.  A total of 105 env gene sequences were PCR-amplified using a 
single genome amplification (SGA) approach and sequenced (median= 3, range= 1; 5 sequences 
per participant).  No more than three ‘double peaks’ per env sequence were tolerated in sequence 
chromatograms across the entire length of env for inclusion in all analyses.  Full-length (n= 16 
participants) and partial (n= 8 participants) env sequences from plasma viruses were available 
for the same time-point for 24 of these individuals (10 TFV and 14 PLB).  These env sequences 
were generated internally (R.  Thebus, C.  Rademeyer, J.  Marais, Z.  Valley-Omar; personal 
communication) (median= 6, range= 1; 26 sequences per participant).   
 
Isolate env sequences were compared to the plasma viruses for each of the 24 participants.  To 
include as much sequence data as possible in the comparisons, alignments were truncated to the 
length of the partial plasma sequences.  The two truncated alignments included one alignment 
from the start of env to the middle of gp41 (sequences between 1911- 1979 bp; HXB2 1- 1443) 
(n= 22 participants) and one that only included the V3V5 (sequences between 603- 642 bp; HXB2 
886- 1407) regions (n= 24 participants).   
 
For each participant, the plasma consensus (T/F) env sequence was derived which was assumed 
to represent the transmitted variant in vivo.  The genetic distance of the isolates and plasma 




diverse than expected compared to the diversity in vivo.  When the maximum DNA distance of the 
plasma consensus sequence was compared in a pairwise manner to plasma and isolate sequences 
for each participant (table 3.2, columns six and seven), no statistically significant difference was 
found (P= 0.1765; Wilcoxon signed-rank test for paired observations).  However, there was 
significantly greater maximum intra-participant pairwise DNA distance within plasma-derived 
envs (table 3.2, columns eight and nine) compared to isolate-derived envs (P= 0.0016; Wilcoxon 
signed-rank test).  Together, this implies that although viral isolation does not capture the full 
diversity in vivo, isolate sequences are a good representation of viruses in vivo.     
 
Nucleotide highlighter plots (fig 3.1 and appendix 3B) allowed for closer inspection of the number 
of synonymous versus non-synonymous mutations in all isolate- and plasma-derived envs.  Figure 
3.1 shows examples of highlighter plots for participants whose sequences matched the plasma 
consensus sequence (fig 3.1a), those that have random changes compared with the plasma 
sequences (fig. 3.1 b and c), and those whose isolate sequences have shared mutations which 
were not detected in plasma variants (fig 3.1d).  The maximum number of non-synonymous 
mutations in plasma and isolate sequences compared with the plasma consensus (table 3.2, 
columns four and five) revealed no statistically significant difference between the two (P= 0.2872; 
Wilcoxon signed-rank test).  There were 12 participants for which non-synonymous mutations 
were present at the same position in all of the isolates envs sequenced which were not present in 
the plasma sequences.  The positions of these shared non-synonymous mutations and the regions 











Figure 3.1.  Highlighter plots comparing plasma and isolate env amino acid sequences for 
four participants.  Highlighter plots show the synonymous (green vertical bars) and non-
synonymous (red vertical bars) nucleotide substitutions for all sequenced env variants in plasma 
and isolate samples (grey vertical lines represent deletions).  Each env sequence is represented 
by a grey horizontal line.  Isolate envs are denoted by a blue bar on the right of the sequences.  
Sequences were aligned to the plasma consensus sequence representing the T/F env sequence 
(labelled ‘CON’ in each figure).  envs with a green arrow to the right of them were selected for 
cloning.  Numbers on the x-axis represent the codon number.  Highlighter plot A is for the CAP303 
alignment which was truncated to the V3V5 region and is one case where the sequenced isolate 
envs are identical to that of the plasma consensus.  Plots B and C show CAP360 (truncated to 
gp41) and CAP301 (full-length env) alignments, respectively, which represent participants with 
low diversity in their isolates and where the isolate envs have minor changes compared to 
variants in the plasma.  Plot D represents CAP323, a participant with greater diversity in the 
isolate env sequences (full length) and where the isolates represent a mixture of variants 








Arm Length of env 
alignment 
Max.  no.  of non-synonymous 
mutations 
Max.  DNA distance from T/F Max.  DNA distance within 
group* 
Plasma seqs Isolate seqs Plasma seqs Isolate seqs Plasma seqs Isolate seqs 
CAP303 PLB V3V5 2 0 0.003 0.000 0.010 0.000 
CAP327 PLB Full-length 1 0 0.001 0.000 0.003 - 
CAP311 PLB Full-length 1 0 0.001 0.000 0.003 0.000 
CAP331 PLB Full-length 2 1 0.001 0.000 0.005 0.000 
CAP301 PLB Full-length 5 2 0.002 0.001 0.005 0.000 
CAP323 TFV Full-length 1 2 0.000 0.001 0.000 0.002 
CAP315 PLB Mid-gp41 4 2 0.003 0.001 0.008 - 
CAP334 TFV Full-length 3 1 0.002 0.001 0.008 0.002 
CAP370 TFV Full-length 2 1 0.001 0.001 0.003 0.000 
CAP320 TFV Full-length 3 3 0.001 0.002 0.003 - 
CAP343 TFV Mid-gp41 2 3 0.002 0.002 0.006 0.002 
CAP317 PLB Mid-gp41 3 3 0.003 0.002 0.005 0.000 
CAP363 TFV Mid-gp41 3 3 0.002 0.002 0.003 0.000 
CAP292 PLB Full-length 1 1 0.003 0.002 0.007 0.002 
CAP326 PLB Full-length  4 - 0.002 - 0.000 
CAP307 PLB Full-length 2 3 0.002 0.002 0.005 0.000 
CAP314 TFV Mid-gp41 4 3 0.003 0.003 0.008 0.000 
CAP345 PLB Full-length 3 7 0.001 0.003 0.000 - 
CAP308 PLB Full-length 4 5 0.002 0.003 0.010 0.002 
CAP360 TFV Mid-gp41 8 5 0.010 0.005 0.037 0.000 
CAP287 PLB Full-length 7 9 0.003 0.005 0.006 0.010 
CAP357 PLB Full-length 0 4 0.001 0.005 0.000 0.002 
CAP375 TFV Full-length 22 21 0.016 0.014 0.022 0.055 
CAP348 TFV Mid-gp41 21 17 0.017 0.015 0.053 0.028 
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Figure 3.2.  Diversity of plasma and isolate envs compared firstly to the 
transmitted/founder env, and secondly to other sequences within the same group.  envs 
were evaluated using an alignment truncated to the V3V5 region of env.  The intra-participant 
diversity was calculated in a pairwise manner for both comparisons.  In the first case, each 
plasma- or isolate-derived env was compared with the plasma consensus env and the maximum 
distance was used for comparison for each.  In the second case, DNA distance was calculated in a 
pairwise manner within the group of isolates or plasma envs for each participant.  Each point 
represents the mean of DNA distances obtained for all sequences from a given participant.  Black 
bars represent the median and IQR.  The PID’s of outlying points are indicated on the figure.  P-
values were calculated using a Wilcoxon signed-rank test for paired observations in STATA.   
 
 
Phylogenetic analysis was performed to assess the relationship between the plasma and isolate 
sequences.  Due to differences in the length of plasma sequences, three comparisons were made: 
one from a full-length env alignment (fig. A3D.1; appendix 3D); and two truncated alignments 
(HXB2 amino acids 1- 481) (fig. A3D.2; appendix 3D), and V3V5 (HXB2 amino acids 296- 469) 
regions (fig 3.3).  All results gave quantitatively similar results with isolate sequences clustered 
with plasma sequences for the same participant and each participant’s set of sequences forming 
a clade.  The V3V5 analysis incorporated all 24 participants and is illustrated (fig. 3.3). 
 
The isolate sequences for 18 of the 24 participants had low diversity and dispersed within the 
plasma sequences indicating that the env diversity of the isolates is similar to that in plasma.  Of 




(CAP348 and CAP360) were classified as having multivariant infections (138), and seven 






Figure 3.3.  A Maximum likelihood tree of HIV-1 env region V3V5 plasma- and isolate-
derived sequences from the same time-point post-infection in each participant.  Nucleotide 
sequences were generated by limit dilution PCR amplification.  Sequences from 24 participants 
from both arms of the trial (PLB depicted in blue, TFV in red) were aligned to a CAPRISA 002 
cohort consensus and a maximum likelihood tree was generated.  Triangles were used to 
represent isolate sequences while circles were used to represent plasma sequences.  Sequences 
were truncated to the V3V5 region to include plasma-derived env sequences which were already 
available for comparison.  This tree was generated using MEGA6.  **denotes participants who 
were identified as having established infection as a result of multivariant transmission.  The 
Subtype C acute consensus sequence was derived from available CAPRISA 002 env plasma 
sequences (n= 592 SGAs) generated from participants infected for less than 3 months.   
 
 
Viruses from CAP348, CAP360 and CAP375 had a high diversity typical of multivariant 




Multiplicity of infection in this cohort was previously identified by Valley-Omar et al (138) who 
identified CAP348 and CAP360 as multivariant transmissions using a heteroduplex tracking assay 
(HTA).  However, CAP375 was identified as a high diversity, single variant transmission by the 
same method.  It is clear from the highlighter plot for CAP375 in appendix 3B, in addition to the 
phylogenetic tree, that CAP375 is a multivariant transmission and thus was misclassified by HTA.  
The isolate sequences from multivariant transmissions show the presence of envs from all 
variants in plasma with the exception of CAP360, which appears to be a single variant 
transmission either because of a bottleneck created in tissue culture- where one variant grew 
preferentially, or it could be a result of under-sampling of isolate sequences.   
 
There were seven participants in this study whose multiplicity of infection was not previously 
classified.  These were classified in this study (using plasma-derived full-length env sequences 
only) by observing the pattern of non-synonymous mutations on the highlighter plots and 
determining whether sequence diversity followed a star phylogeny using the Poisson-Fitter tool 
(171) on the Los Alamos database (table 3.4).  For single variant transmission, we expected a low 
intra-participant diversity, a star-like phylogeny and Poisson distribution of Hamming distances.  
We also expected the clinically estimated days post-infection to fall within the estimated 
timeframe of infection based on the estimated time from the most recent common ancestor 
(MRCA).  Based on this definition, four infections (CAP326, CAP331, CAP345 and CAP357) were 
classified as single variant infections.  Conversely, sequences were classified as multivariant 
transmissions if there was high genetic diversity with a multimodal distribution of pairwise 
Hamming distances, a non-star-like phylogeny and/or if one or more sequences were noticeably 
different from others in plasma.  Based on these criteria, two sequences were classified into this 
















Table 3.4.  Genetic complexity of plasma viruses classified for participants who had not been 























CAP287 PLB 6 
99  
(19, 179) 
58 0.4 No Multiple 
CAP301 PLB 6 
100 
(80, 120) 
25 0.5 No Multiple 
CAP311 PLB 2.7 
44  
(N/A) 
42 0.2 No Undetermined** 
CAP326* PLB 2.3 
44 
(14, 73) 
23 0.3 Yes Single 
CAP331 PLB 3.4 
56 
(35-78) 
43 0.2 Yes Single 
CAP345 PLB 2 
33 
(-5, 71) 
43 0.2 Yes Single 
CAP357 PLB 1 
17 
(1,32) 
25 0.1 Yes Single 
CAP375 
(reclassification) 
TFV - - 36 2.3 - Multiple 
*The plasma sequences used to classify this variant were variants present at the time of 
enrolment; one week prior to the plasma sample used to isolate the participant’s virus 
**Sequences had a low diversity amongst plasma SGAs but they did not fit the model of random 
evolution (a star phylogeny) therefore, multiplicity of infection could not be determined 
 
 
CAP287, although the estimated date of infection was within the range calculated for date to 
MRCA, was classified as multivariant due to the presence of a highly diverse second variant 
represented by one out of six plasma sequences.  CAP301 was classified as multivariant due to its 
maximum DNA distance between sequences being high and also the estimated date of infection 
according to Poisson-fitter being 75 days after the clinical estimate.  The highlighter plot of 
CAP301 also shows the presence of a closely related, but distinct, second variant.  CAP311 
remains unclassified because even though it does not follow a star phylogeny, the number of 
sequences and the low diversity does not allow multiplicity of infection to be determined with 
certainty.   
 
When these results were put together with those published (138), it was found that 17 out of 21 
(81%; 95% CI, 63%- 99%) women in the PLB arm were infected with a single virus, compared to 




tailed Fisher’s exact test).  This result supports the previous finding which showed that TFV gel 
did not affect the genetic bottleneck (138). 
 
 
3.3 Genotypic characteristics of env do not differ between viruses from the TFV 
versus the placebo arm 
 
Variable loop characteristics of viral envelopes are determinants of cell tropism and entry, and 
may undergo selection during transmission, with subtype C viruses from acute infection having 
shorter loop lengths and fewer glycosylation sites than envs from viruses in chronic infection (24, 
39).  Variable loop charge has been implicated in a number of functions depending on the region 
being investigated.  For example, V1, V2 and V3 charge plays a role in fusion capacity and 
coreceptor tropism (173, 174).  In addition, isolates from end-stage disease with enhanced fitness 
displayed a higher net charge of gp120 (175).  We hypothesized that if TFV affected the barrier 
to infection, then these characteristics may differ between trial arms.  Examination of altered loop 
length, charge or predicted sites of glycosylation between viruses of the TFV and PLB arms (fig. 
3.4) showed that there was no significant difference between the trial arms for any of the 
characteristics investigated, including loop length, glycosylation, or charge (P> 0.05; two-tailed t-
test or a two-tailed Wilcoxon rank-sum test for independent samples depending on the 






Figure 3.4.  Variable loop characteristics of envs from PLB and TFV arm isolates do not 
differ.  For a given characteristic within each variable loop, the average for all isolates sequenced 
for each participant is represented as a point in a column.  The median and IQR is represented by 
the black bars overlapping points in each column.  Statistical significance was determined by 
performing either a two-tailed t-test or a two-tailed Wilcoxon rank-sum test for independent 
samples in STATA (depending on the distribution of the data for each characteristic in each loop).  
All P-values were greater than the significance cut-off of 0.05.   
 
 
Previously it has been shown that transmission selects for viruses which are more like consensus 
in amino acid identity (of Gag, Pol and Nef protein sequences) compared to chronic variants (50).  
Consensus-like variants are thought to have a higher in vivo fitness as they represent viral 
variants which are able to replicate to a majority in infected individuals, although they have not 
been shown to replicate more efficiently in vitro (48).  Furthermore, factors that increase or 
decrease the transmission barrier such as female-to-male transmission, the presence of genital 
ulcers or inflammation, were shown to increase or decrease this selection bias for consensus-like 
variants (50).  To identify whether breakthrough viruses from the TFV arm were more consensus-
like than those of the PLB arm in Env, isolate sequences were compared to the CAPRISA 002 
subtype C consensus derived from SGAs (n=592) generated from participants infected for less 




between isolate sequences and the CAP 002 consensus indicate that there is no difference 
between trial arms in the nucleotide or amino acid distance from consensus of isolate env 
sequences (fig 3.5; two-sample t-test on data with equal variances).  On the contrary, a trend can 
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Figure 3.5.  The distance to consensus does not differ between TFV and PLB arm isolates.  
Isolate env sequences were aligned to a CAPRISA 002 consensus sequence and the pairwise 
nucleotide (left) and amino acid (right) distances were calculated using MEGA6.  The average of 
all distances for a given participant’s sequences is plotted above with each participant 
represented by either a blue circle (PLB) or a red square (TFV).  Black bars represent the mean 




3.4 Phenotypic characteristics of Env do not differ between viruses from the TFV 
versus the placebo arm 
 
Viral fitness is defined as the ability of a virus to survive and replicate within a given setting and 
fitness can be conferred by an increase in efficiency in any of the steps of the viral replication 
cycle, which would in turn increase its replicative capacity [reviewed in (176)].  Inhibition assays 
are a convenient way of measuring viral dependence on a particular step of the replication cycle 
by blocking that step.  This method can uncover functional differences between viruses in relation 
to one another.  Hence, we investigated the effect of various inhibitors on virus replication.  
Inhibition sensitivities of the isolates were determined using the effective inhibitory 
concentration, that is, the concentration at which viral replication, measured as RLU, was 





Susceptibility to TFV 
The CAPRISA 004 trial found no evidence of TFV resistance based on genotypic data (95, 118).  
However, Lehman et al. (177) postulate that if TFV is present in the mucosa after participants 
became infected (pre-seroconversion) then viruses may have gained polymorphisms which allow 
it to replicate better in the face of sub-optimal levels of the drug.  Here, we inhibited the 
replication of isolates in tissue culture using TFV, firstly, to confirm that TFV arm viruses are not 
phenotypically resistant to TFV, and secondly, to determine if a difference in susceptibility was 
associated with women who became infected while using TFV gel. 
 
Resistance to TFV was preciously defined as a 0.4 to 2.2-fold change in inhibitor sensitivity when 
compared with that of HIV-1 IIIB (178).  All isolates were fully inhibited by TFV (fig. A3E.1 in 
appendix 3E) with a median EC50 of 2872 nM.  The two viruses that had the highest EC50s for TFV 
were CAP292 and CAP307 with EC50s 1.6-fold higher and 1.5-fold higher than the median, 
respectively.  In addition, there was no difference in isolate susceptibility to TFV between study 
arms (fig. 3.6), with all TFV arm inhibition curves falling within the range of PLB arm inhibition 
curves.  This indicates that there was no phenotypic resistance within our TFV arm isolates. 
 
 
Susceptibility to entry inhibitors 
To investigate if certain phenotypic properties associated with viral entry were enriched in the 
TFV arm, we assayed viral attachment using CCR5 dependence (non-competitive CCR5 binding) 
by inhibiting with maraviroc (MVC), CD4 binding affinity with anti-CD4 antibody clone SK3 
(referred to as anti-CD4 from here onwards), and CCR5 binding affinity with the use of PSC-
RANTES.  Fusion capacity was assayed using T20 which prevents fusion of the viral and host 
membranes.  We used JM-2987, a CXCR4 binding inhibitor, to investigate whether any of the 
isolates could utilize CXCR4 as a coreceptor (see appendix 3D for all inhibition curves).   
 
TFV, PSC RANTES and anti-CD4 all had narrow distributions of EC50’s (fig. 3.6), whereas the 
distributions of isolate sensitivities to T20 and MVC were wider with ranges of 1.5 nM to 27 nM, 
and 0.68 nM to 17.37 nM, respectively.  There was no difference to any of the inhibitors between 
isolates between isolates from the different study arms (fig 3.6; Wilcoxon rank sum test for 
independent observations).  All isolates were sensitive to MVC and PSC-RANTES, indicating that 
they utilized CCR5 as a coreceptor (fig. 3E.3 and 3E.5, respectively; appendix 3E).  In addition, 
none of the viruses displayed susceptibility to the CXCR4 inhibitor JM-2987 (fig. 3E.6; appendix 
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Figure 3.6.  Inhibition sensitivities of isolates do not differ between trial arms.  Inhibition 
sensitivities represented as effective inhibitory concentrations (EC50) are represented on the x-
axis.  Each point on the graph represents an isolate from a given participant.  Viruses from the 
PLB arm are represented as blue circles while those from the TFV arm are represented as red 
squares.  The black bars represent the median and IQR for each group.  All P-values on this figure 
were calculated using a Wilcoxon rank sum test for independent observations in STATA. 
 
 
There are a few outliers on each of the plots (fig 3.6).  The isolates with a lower susceptibility to 
T20 were CAP353 and CAP326 in the PLB arm, and CAP343, CAP320 and CAP325 in the TFV arm.  
There were three isolates with higher MVC EC50s than all other isolates: CAP292, CAP326 and 




(PLB arm) exhibited an inhibition plateau at 18% infection and below 10% infection, respectively 
(fig. 3.7), suggesting that these isolates can still enter cells despite the CCR5 co-receptor being 
blocked by MVC. 
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Figure 3.7.  Maraviroc inhibition plateaus for CAP291 and CAP292 suggesting that these 
isolates can still use CCR5 despite the presence of MVC.  The graph shows the decrease in the 
percentage infection (y-axis) by the isolates on TZM-bl cells with increasing MVC concentration 
(x-axis).  CAP291 inhibition is represented by the red curve while CAP292 inhibition is 
represented by the blue curve.  BAL (know R5-tropic isolate) was used as a control virus and is 
represented in black. 
 
 
Noticeably, CAP292 and CAP326 were less susceptible to MVC and PSC-RANTES while being more 
susceptible to anti-CD4 than the median of the isolates from the PLB arm.  This implies that these 
viruses had a greater CCR5 binding capacity and CCR5 affinity, while having a lower CD4 binding 
affinity than the majority of isolates from the PLB arm.  CAP326 was also less susceptible to T20, 
suggesting that this virus had a greater fusion capacity.  CAP325, a TFV arm isolate, was less 
susceptible to T20 and more susceptible to anti-CD4 inhibition than the majority of TFV arm 







To evaluate the role of Env directly, PSVs were constructed which only differed in Env and not in 
any other viral proteins.  The entry of Envs was examined to determine whether they differed 
between viruses from the two trial arms.  For each participant, Env-typed PSVs were generated 
by cloning the env most representative of the majority isolate.  In the highlighter plots for each of 
the participants (figure 3.1 and appendix 3B), the sequences which were selected for cloning are 
indicated by a green arrow and can be compared in relation to both plasma and isolate sequences.  
Of the 28 participants selected for phenotypic comparison (14 TFV and 14 PLB), PSVs were 
produced for 10 participants from the TFV arm and 9 participants from the PLB arm.  Since 
CAP348 was identified as a multivariant infection, two env genes were cloned (one representing 
each transmitted virus), and the overall entry efficiency was calculated as the average entry 
efficiency of both clones.  After multiple attempts at cloning CAP345, CAP283, CAP315, CAP343 
and CAP257, no functional clones could be generated.  Of the 20 functional PSV clones generated, 
17 were identical to the isolate SGA amplicon while two differed in a single site.  The final one, 
CAP287, had two synonymous and three non-synonymous changes compared with the SGA that 
was sequenced.  These are too many changes to have been introduced during PCR and cloning.  
As all of the non-synonymous mutations in CAP287 were present in vivo, but in two different 
plasma variants, we concluded they were probably real changes as opposed to PCR-induced 
errors.  Most likely  when the sample was taken from the first round product for second round 
PCR prior to cloning, we amplified a different variant to the one sequenced, which was present as 
a minor variant in the first round product.  Table 3.5 shows the participants for which non-
synonymous mutations were introduced during the cloning process and the possible functional 
implications of these changes.   
 
 
Table 3.5.  Non-synonymous changes introduced into pseudoviruses envs during the cloning 
process 
 
Participant ID Number of non-
synonymous changes* 
Location & possible functional implications, if 
known 
CAP360 1 V3 loop; possible effects on coreceptor binding 
CAP323 1 C1; none known 
CAP287 3 Any functional changes would still reflect an in vivo-
relevant phenotype 






Finally, the in vitro entry efficiencies of PSVs were assessed in order to determine if they differ 
between the trial arms (fig 3.8).  Following a two sample t-test on log-transformed data it was 
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Figure 3.8.  Entry efficiency does not differ between trial arms.  Entry efficiency of env-typed 
PSVs was assessed using a single cycle replication assay on TZM-bl cells.  The figure shows the 
entry efficiency expressed as RLU per pg of p24 in infection experiments with each PSV stock.  
Each point on the graph represents one PSV.  Black bars represent the mean and 95% CI for both 
data sets.  P-values were calculated by performing a two-sample t-test on log-transformed data 



























3.5 Env phenotype does not correlate with predictors of  disease progression 
 
In order to determine whether Env phenotype can impact disease progression in this cohort, we 
investigated whether inhibitor sensitivity and viral entry efficiency (i.e.  PSV infectivity) 
correlated with VL and/or CD4 count.  There was no correlation between inhibitor sensitivity and 
predictors of clinical progression (VL and CD4 count) (table 3.6).   
 
 
Table 3.6.  Spearman correlation coefficients and P-values showing the relationship between 
inhibition sensitivities to each inhibitor and various clinical markers of infection for the isolates 
 
 CORRELATION WITH 
Inhibitor VL at isolation VL at 3 months 
post-infection 
VL at set-point CD4+ count at set-point 










































In addition, entry efficiency measured using a PSV entry assay did not correlate with VL at 
isolation (P= 0.5520), at 3 months post-infection (P= 0.6165) nor with VL at set-point (P= 0.2272) 
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Figure 3.9.  Entry efficiency does not correlate with viral load at various time-points post-
infection.  Entry efficiency for all PSVs is depicted on the x-axis while the VL at A) isolation, B) 3 
months post-infection (p.i); and C) set-point is depicted on the y-axis.   A Shapiro-Wilk test for 
normality was used to determine distribution of the data and then a Spearman rank correlation 




3.6 Pseudovirion Envs differ in sensitivity to entry inhibitors when compared with 
the corresponding  isolate 
 
It is known that native env trimers and PSV envs differ in terms of their glycosylation (179), the 
percentage at which they are present on the surface of virions and also the degree to which they 
are processed (180); all of which can affect the function of PSVs relative to their corresponding 
isolate.  In order to evaluate the PSV system to determine whether PSVs are representative of 
isolates, the inhibition sensitivities of PSVs were compared to that of their corresponding isolates 
(fig 3.10).  The PSVs which sustained PCR-induced errors compared with their corresponding SGA 




Inhibition curves of the isolate and corresponding PSV can be found in appendix 3F.  Median EC50 
values for PSVs and isolates for each inhibitor are shown below (table 3.7). 
 
Table 3.7.  Median inhibition sensitivities for the comparison of pseudoviruses and isolates. 
 
Inhibitor Median EC50- Pseudoviruses 
(IQR) 
Median EC50- Isolates 
(IQR) 


















It was found that PSVs were 5-fold less susceptible to inhibition by T20 (P= 0.0117), and 3-fold 
and 19-fold more susceptible to inhibition by the anti-CD4 antibody SK3 (P= 0.0117) and PSC-
RANTES (P= 0.0117) respectively, than isolates.  The significance was retained even after 
Bonferroni correction (P-value< 0.0125 for significance).  Since a Wilcoxon signed-rank test for 
paired data was employed to test the difference between PSV and isolate inhibition in all cases, 
the ranks of participant EC50’s within each group can be concluded to be different.  Interestingly, 
there was no significant difference between PSV and isolate sensitivity to MVC (1.5-fold 
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Figure 3.10.  Inhibition sensitivities of pseudoviruses compared with their corresponding 
isolate.  EC50 values representing the effective inhibitory concentrations for 50% inhibition are 
shown on the y-axis for various inhibitors (indicated above each graph). Black bars represent the 
median and IQR for the data.  The P-values were calculated using a Wilcoxon signed-rank test for 
paired data and are significant for T20, anti-CD4 antibody clone SK3 and PSC-RANTES even after 























Effective prevention modalities are essential if the trajectory of HIV-1 infection in Africa is to be 
curtailed; especially in young women who bear a disproportionate amount of the infection 
burden.  TFV-based microbicides, if used correctly, are a safe, effective, and convenient means of 
protection from infection, which provides women with control over their own protection.  
However, when breakthrough infections occur, a potential pitfall may be that this barrier which 
is only partially protective might select for more virulent viruses during transmission (181).  In 
the case of the CAPRISA 004 trial, the partial protection conferred by the microbicide could result 
in transmission of viruses with characteristics that may hasten disease progression or worsen 
clinical symptoms (119).  Therefore, this study investigated the transmission of Env variants in 
the CAPRISA 004 1% TFV trial in order to characterise early viral variants within the CAPRISA 
004 cohort, in order to identify differences in characteristics of early viruses between trial arms, 
and to determine their potential effect on clinical markers of disease progression.  
 
One observation suggests the transmission of more virulent viruses in the TFV arm of the study.  
Garrett et al. found a difference in VL between study arms with participants in the TFV arm having 
higher VL over time (up to two years post-infection) than those in the PLB arm, despite being 
assigned to gel use (119).  The authors state that the VL difference is explained partially by the 
higher number of participants in the PLB arm with protective HLA alleles.  In the subset of 48 
participants chosen for this study, VLs were found to be similar between trial arms at 3 months 
post-infection and at set-point.  This could be due to the fact that trial arms were matched for the 
presence of protective HLAs when selecting the cohort for this study.   
 
In fulfilment of the first objective of this study, clinical isolates were obtained for 39 women by 
isolating HIV-1 from cryopreserved plasma and culturing isolated virions in uninfected donor 
PBMCs.  One of the drawbacks of using PBMCs to isolate HIV-1 is that donor cells may have 
differential susceptibility to infection by HIV-1 (160).  To overcome this, a 3x3 stimulation 
protocol was employed where PBMCs were obtained from three different donors and stimulated 
under three different conditions (132, 161) to obtain a mix of PBMCs each time cells were added.  
This resulted in a high percentage (81%) of primary isolates being obtained.   
 
The next objective was to determine whether the primary isolates used in this study were 
genotypically representative of viruses circulating in the plasma of these individuals.  There have 
been a number of studies showing that PBMC-cultured viruses do not represent variants in vivo  




env (183, 184).  These studies found outgrowth of minor variants from infected PBMCs in the 
isolates.  Other studies have found that isolates are similar to variants in vivo (160, 185), by 
comparing proviruses in the donor with proviruses in recipient PBMCs after co-culture.  Most 
recently, Dalmau et al. have shown (using a deep sequencing approach) that viruses isolated from 
plasma, infected donor PBMCs, and sequences obtained from plasma RNA do not differ, and that 
unique variants are infrequent (186).  Following these findings, we wished to confirm that our 
isolates were representative of circulating variants (sequences generated from plasma RNA).  We 
compared the isolate env sequences to plasma-derived envs for 24 participants.  The maximum 
intra-participant diversity from the plasma-derived T/F sequence (assumed to represent the 
virus that founded clinical infection) was not greater in the isolates than the plasma variants, 
indicating that there was little- to no diversification of isolate sequences during growth in tissue 
culture. However, the maximum intra-participant pairwise distance was greater in the plasma 
than in isolate env sequences; indicating that the isolates represent some, but not all of the 
diversity of the quasispecies in vivo.  This is consistent with findings from the studies which 
showed preferential expansion of certain variants over others when HIV-1 was isolated on PBMCs 
(182–184).  Our study was limited by the small number of env SGAs generated per participant 
which could, in some cases, lead to under- or overestimation of the diversity within isolates 
compared with plasma sequences.  The case of CAP323 is a good example.  Three of the five 
isolates sequenced had a non-synonymous mutation that was not present in any of the five 
plasma sequences that we had available.  This could represent outgrowth of a variant that 
sustained a mutation during growth in tissue culture, although the fact that so few plasma 
sequences were available could mean that the variant that grew was a minor variant in plasma.   
However, as in most cases the env sequences sampled from the isolates were similar to sequences 
in the plasma, and the env genes of isolates were genotypically representative of plasma variants 
(cell-free), we concluded that it was suitable to use primary isolates for further comparisons.   
 
The third objective was to characterise viruses genotypically and compare env characteristics 
between study arms.  We attempted to classify the multiplicity of infection for seven participants 
not classified previously (138).  Two were classified as multivariant infections, four were single 
variant infections and one, CAP311, remained undetermined.  CAP311 posed difficult to classify 
due to the fact that plasma envs had a low diversity and a small hamming distance amongst 
sequences, but mutations did not follow a random distribution.  Further sequencing would be 
needed to resolve the multiplicity of infection in this participant.  An eighth participant, CAP375, 
which was previously classified as a single variant transmission with high diversity (138), was 
reclassified as a multivariant transmission.  These results put together with the previous studies’, 




use had no impact on the transmission bottleneck.  Thus, this study adds to the picture of 1% TFV 
gel being safe for use as a microbicide (95, 187, 188).  
 
The genital mucosa provides an efficient barrier to HIV infection.  Several lines of evidence 
suggest that transmission is not entirely stochastic but might involve selection of  viruses with 
favourable characteristics that can overcome this barrier to establish a local focus of infection 
(24, 47, 50).  T/F viruses, and more specifically their Envs, differ from viruses during chronic 
infection in a number of ways.  For example, T/F Envs have shorter variable loop lengths and 
fewer glycosylation sites than chronic Envs (24, 44–46).  Assessing loop length and glycosylation 
in early infection may give insight to the transmission fitness of the T/F.  We found no difference 
in the median loop length, charge or number of predicted glycosylation sites in any of the variable 
loops between trial arms when assessing isolate Env sequences.  This finding suggests that there 
may not be selection for viruses with Env characteristics that favour greater transmission fitness 
in women assigned to TFV gel use.   
 
Another characteristic associated with heterosexual transmission of subtype C viruses is the 
selection of viruses which are more consensus-like in amino acid identity (48).  A consensus-like 
identity is a proxy for transmission fitness, therefore, viruses which are more similar to consensus 
are more likely to be transmitted.  We found no difference between trial arms in nucleotide 
identity of the isolates when compared to a CAPRISA 002 cohort consensus (subtype C).  There 
was a trend towards isolates from the TFV arm being less consensus-like compared with PLB arm 
isolates; however, this did not reach statistical significance.  If this association is real, then it 
would suggest that TFV use is associated with reduction in selection during transmission.  An 
increased sample size would be needed to verify this result. 
 
Our fourth objective was to identify the isolates’ phenotypic characteristics and compare them 
between study arms.  Therefore, we assessed the susceptibility of the isolates to TFV in vitro to 
determine if differences in susceptibility to TFV could have contributed to breakthrough 
infection.  Tenofovir based PrEP has been a concern due to the possibility of selection of viruses 
with resistance mutations to TFV which could ultimately harm prevention and treatment efforts.  
Resistance is most commonly developed if PrEP is initiated during undiagnosed infection (189) 
and evidence suggests that subtype C strains have a lower barrier to resistance [reviewed in 
(190)].  In addition, there have been cases of breakthrough infections due to transmitted drug 
resistance in patients on oral PrEP [reviewed in (189)].  However, previous studies have shown 
no transmitted resistance in participants assigned to TFV gel use in the CAPRISA 004 cohort based 




isolates by TFV was observed with all TFV inhibition curves falling within the range of PLB 
inhibition curves.  Furthermore, susceptibility to TFV did not differ between study arms 
indicating that TFV use was not a factor influencing breakthrough infection.   
 
All isolates were confirmed phenotypically to be exclusively R5-tropic since they were all 
sensitive to the CCR5 binding inhibitors MVC and PSC-RANTES, but were not sensitive at all to 
inhibition by bicyclam JM-2987, a CXCR4 binding inhibitor.  The early viruses in this study reflect 
previous findings that transmitted and early viruses are R5-tropic.  In addition to co-receptor 
tropism, MVC as a non-competitive CCR5 inhibitor, was used to measure CCR5 dependence and 
PCS-RANTES, as a competitive CCR5 inhibitor, was used to assess co-receptor binding affinity.  
Neither of these traits differed between isolates from the trial arms.  Ping et al. (39) described the 
presence of two conformations of CCR5 molecules on the surface of cells, a MVC resistant, and a 
MVC sensitive kind.  Transmitted viruses almost exclusively use the MVC sensitive CCR5 to enter 
cells, while viruses from chronic infection are able to utilize the MVC resistant kind, reaching an 
inhibition plateau at 10% infection when CCR5 expression on the cell surface is high.  Other 
groups have described similar observations of viruses that are able to utilize MVC-bound CCR5 
(191).  Interestingly, CAP291 (TFV arm) and CAP292 (PLB arm) both exhibit a MVC inhibition 
plateau, CAP291 at around 18% infection, and CAP292 below 10% infection.  However, CAP291 
was isolated from plasma sampled at approximately 11 weeks post-infection and CAP292 from 
plasma sampled at five weeks post-infection.  This is too early to be considered chronic infection 
which perhaps suggests that these viruses represent a transmitted phenotype from donors who 
were in chronic stages of infection. 
 
Neither fusion capacity, nor CCR5 dependence and binding capacity, nor CD4 binding capacity, 
differed between trial arms.  There were, however, two isolates from the PLB arm and one from 
the TFV arm that showed decreased susceptibility to binding and fusion inhibitors, respectively 
with a concomitant decrease in CD4 binding affinity.  This finding underlines the synergistic 
nature of the various stages of entry in determining overall entry efficiency.  We evaluated the 
overall entry efficiency directly using PSVs expressing the majority Env of the isolates and found 
that entry efficiency did not differ between study arms.  Thus, phenotypic characteristics of Env 
do not differ between viruses from the TFV and PLB arms of the CAPRISA 004 trial. 
 
Our fifth objective was to evaluate whether sensitivity to inhibitors, or entry efficiency, correlated 
with VL at isolation, 3 months, and set-point, or CD4+ T cell count at set-point.  Neither entry 
efficiency, nor sensitivity to inhibitors correlated with either CD4+ count at set-point or VL at any 




CCR5 binding affinity, CCR5 dependence, fusion capacity and entry efficiency does not contribute 
to clinical markers of disease progression in this cohort.   
 
Finally we evaluated the PSV system in measuring characteristics of entry.  The PSV assay is a 
widely accepted, convenient way of examining entry efficiency and evaluating host immune 
responses or candidate vaccines against HIV-1 (neutralising antibodies).  Recently however, the 
functionality and neutralization sensitivity of PSVs was shown to differ from IMCs where the Env 
and backbone were a subtype match versus if they were mismatched (192).  Similarly, we found 
an altered susceptibility of PSVs to certain entry inhibitors when compared with their 
corresponding isolate.  Isolates were more susceptible to inhibition of fusion and less susceptible 
to inhibition of CD4 binding and CCR5 binding than PSVs.  This could be due to the fact that Env 
incorporation has been found to be less efficient in PSVs and depends on the ratio of backbone to 
Env plasmid used when generating the PSVs (180).  In addition, PSVs can differ greatly in the 
amount of fully processed Envs on the virion surface.  This decrease in functional Env could lead 
to differences in CD4 and CCR5 binding efficiency.  The lack of a difference in sensitivity between 
isolates and PSVs to MVC indicates that dependence on CCR5 binding does not differ between 
PSVs and isolates.  This seems to contradict the difference in sensitivity to PSC-RANTES between 
isolates and PSVs.  However, MVC merely decreases the amount of CCR5 available on the cell for 
use by the virus for entry and does not competitively inhibit CCR5 binding.  Thus, generating PSVs 
may affect Env’s ability to bind CCR5 but does not affect the amount of CCR5 needed to enter cells. 
 
While only one env per isolate was cloned for all participants in this comparison, the env chosen 
was a majority variant within the isolates and therefore represents the env of the virus replicating 
most efficiently within the isolate stocks.  This data highlights the importance of the context in 
which we study HIV-1 proteins.  For example, the LLP domains in the cytoplasmic tail (CT) of 
gp41 (which interacts with the Gag matrix (MA) protein) have been implicated in Env 
fusogenicity, protein stability and cell surface expression [reviewed in (193)].  Hence, if these CT-
MA interactions are changed in any way it may affect the fusogenicity and stability of Env.  
Similarly, the apparent affinities of CD4 and CCR5 binding might be affected as these CT-MA 
interaction have also been shown to be important for Env incorporation into virions (193–195).   
The concern that this raises is two-fold: firstly, evaluating different Envs expressed in the same 
backbone can have differential effects on each Env being studied, and secondly, evaluating 
subtype C Envs in a subtype B backbone may affect Env function across all Envs and differentially 
between Envs (192).  While we do not have data for homologous Env-backbone PSVs, the 





Overall, our study confirms that 1% TFV gel use does not affect the genetic bottleneck, and further 
shows that gel use does not select for an altered Env phenotype which may lead to worsening of 
clinical symptoms such as higher VLs and lower CD4 counts.  Although this study only evaluates 
Env, Chopera et al. have also shown no difference in Gag-Pro fitness and Nef function between 
study arms (146).  This means that, in addition to a slightly higher number of protective HLA-
bearing participants in the PLB arm (119), other factors are responsible for the VL difference 
between study arms.  Further investigation into the causes of this VL discrepancy is needed. 




In summary, the analysis of early viruses from participants who became infected while enrolled 
in the CAPRISA 004 1% TFV gel microbicide trial showed that the genetic bottleneck was not 
affected by the use of 1% TFV gel and that viruses from the both study arms were similar in 
genotypic and phenotypic characteristics of their Envs.  Furthermore, characteristics of Env did 
not correlate with disease progression or VL at isolation, 3 months or at set-point, regardless of 
trial arm.   Overall this suggest that the partial protection of 1% TFV gel does not result in the 
selection of viruses that worsen disease outcome and further supports the use of TFV as a safe 























Appendix 1.  Reagents and buffers 
 
The materials described hereafter and the methods in which they can be used are described in 
Molecular Cloning: A Laboratory Manual (196). 
For Carbenicillin:  (100 mg/mL) - stored at -20OC 
 
1. Weigh 1000 mg carbenicilin disodium salt (98-100% anhydrous) 
2. Dissolve in 10 mL distilled, de-ionized H2O in a 15 mL tube 
3. Vortex to ensure that all the salt is dissolved   
4. Using a syringe, pass the solution through a 0.22 µm filter into a fresh, sterile tube 
 
 
For Luria-Bertani Broth : -stored at room temperature 
 
1. Add the following to 800 mL H2O:  
10 g Bacto-tryptone 
5 g yeast extract 
10 g NaCl 
2. Adjust pH to 7.5 with NaOH or HCl 
3. Adjust the volume to 1 L with dH2O 
4. Sterilize by autoclaving at 121OC for 15 minutes 
 
For Luria-Bertani Agar: -stored at 4OC 
 
1. Add the following to 800 mL H2O:  
10 g Bacto-tryptone 
5 g yeast extract 
10 g NaCl 
2. Adjust pH to 7.5 with NaOH or HCl 
3. Add 15 g agar and dissolve by heating in the microwave 
4. Adjust the volume to 1 L with dH2O 






Pouring agar plates: 
 
1. Prepare LB Agar as above and allow to cool 
2. Add 1 µL carbenicilin (100 mg/mL as above) per mL of agar using sterile technique 
3. Add to sterile petri dishes until the height of the liquid ~1 cm thick 
4. Allow to set before storing the plate with the lid facing down 
 
 
For Tris- buffered saline (TBS) buffer:  -stored at 4OC for up to 3 months 
 
1. Dissolve 6.05g Tris and 8.76g NaCl in 800mL H20 
2. Adjust to pH 7.6 with 1M HCl 





















Appendix 2.  Table A2.  HIV-1 subtype C envelope, full-length primers. 
 
Primer Name Sequencing 
Direction 
Primer Sequence Length 
(mer) 
HXB2 position of 
first 5’ nucleotide 
EF00 Forward 5' GGG AAA GAG CAG AAG ACA GTG GCA ATG A 3' 28 6204 
EF15 Reverse 5' CTT GCT CTC CAC CTT CTT CTT C 3' 22 8442 
EF55 Reverse 5' GCC CCA GAC CGT GAG TTG CAA CAT ATG 3' 27 7937 
EF115 Reverse 5' AGA AAA ATT CTC CTC TAC AAT TAA 3' 24 7371 
EF170 Forward 5' AGC AGG AAG CAC TAT GGG 3' 18 7802 
EF175 Reverse 5' TTT AGC ATC TGA TGC ACA GAA TAG 3' 24 6398 
EF200 Forward 5' GGG ATA ACA TGA CCT GGA TGC AGT GGG 3' 27 8095 
EF260 Forward 5' TTC AGC TAC CAC CGA TTG AGA GAC T 3' 25 8523 
For14 Forward 5' TAT GGG ACC AAA GCC TAA AGC CAT GTG 3' 27 6559 
For16 Forward 5' TTT AAT TGT GGA GGA GAA TTT TTC TA 3' 26 7353 
Rev 15 Reverse 5' CTG CCA TTT AAC AGC AGT TGA GTT GA 3' 26 7012 
Rev19 Reverse 5' ACT TTT TGA CCA CTT GCC ACC CAT 3' 24 8817 
  
 




Appendix 3A. Table A3A.  A description of the CAPRISA 004 participants selected for this study.
TFV arm 
participant 




Viral load Ɨ Time Post-infection Protective 
HLA? ɸ Weeks Days Weeks Days 
CAP304 X 94 900 5 34  CAP321 338 000 5 35 No 
CAP305 X 45 600 11 77 No CAP337 114 000 10 71 Yes 
CAP310 X 305 000 4 29 No CAP303 344 000 4 29 No 
CAP314 166 000 12 87 Yes CAP340 X 72 500 13 89 No 
CAP320 37 500 5 34 Yes CAP345 130 000 6 43 No 
CAP325 127 000 3 20 No CAP327 91 600 3 20 No 
CAP343 130 000 7 51 Yes CAP317 351 000 7 51 No 
CAP355 19 700 5 32 No CAP353 487 000 5 32 No 
CAP360 80 600 3 24 Yes CAP301 33 500 4 25 Yes 
CAP362 X 44 200 4 29 Yes CAP335 X 214 000 4 28 No 
CAP363 97 500 5 36 No CAP292 458 000 5 38 No 
CAP367 3 360 000 3 22 No CAP326 31 500 3 23 No 
CAP283 12 900 7 52 No CAP306 141 000 8 54 Yes 
CAP291 14 300 11 79 No CAP349 950 000 11 77 No 
CAP318 22 300 5 37 No CAP307 174 000 5 37 No 
CAP323 22 000 3 22 Yes CAP315 108 000 3 22 Yes 
CAP334 21 200 6 42 Yes CAP311 18 600 6 42 No 
CAP348 305 000 8 57 Yes CAP287 13 200 8 58 No 
CAP352 113 000 7 50 No CAP365 14 500 9 63 Yes 
CAP358 X 717 9 66 No CAP308 37 100 9 66 No 
CAP368 1 180 4 31 Yes CAP351 X 151 000 4 28 No 
CAP370 28 800 5 33 Yes CAP331 12 700 6 43 No 
CAP372 107 000 3 21 Yes CAP330 X 21 200 2 15 No 
CAP375 192 000 5 36 Yes CAP357 14 900 7 47 No 
X Indicates participants whose viruses could not be isolated in tissue culture; Ɨ viral load of sample used for isolation;  




























Figure A3B.  Highlighter plots comparing plasma and isolate env sequences for 20 participants.  
Highlighter plots show the synonymous (green) and non-synonymous (red) nucleotide 
substitutions for all sequenced env variants in plasma and isolate samples (grey vertical bars 
represent deletions).  Each env sequence is represented by a grey horizontal line.  Isolate envs are 
denoted by a blue bar on the right of the sequences.  Sequences were aligned to the plasma 
consensus sequence representing the T/F env sequence (labelled ‘CON’ in each figure).  envs with 
a green arrow to the right of them were selected for cloning.  Numbers on the x-axis represent 
the codon number.  Highlighter plot A is for the CAP303 alignment which was truncated to the 
V3V5 region and is one case where the sequenced isolate envs are identical to that of the plasma 
consensus.  Plots B and C show CAP360 (truncated to gp41) and CAP301 (full-length env) 
alignments, respectively, which represent participants with low diversity in their isolates and 
where the isolate envs have minor changes compared to variants in the plasma.  Plot C represents 
CAP323, a participant with greater diversity in the isolate env sequences (full length) and where 
the isolates represent a mixture of variants sequenced from plasma and those not seen in the 




Appendix 3C.  Table A3C.  Non-synonymous mutations shared in isolates envs that were not 




HXB2 Env gp160 position 
(change from T/F) 
Known function(s) of residue or region Reference(s)
* 





After N460 (deletion of 
three amino acids, SRI) 
 
Adjacent to V85, a gp120 point of contact with gp41  
 
Adjacent to K117, a coreceptor binding site outside 
of V3 
 
V5 hypervariable loop close to CD4 contact residue 
S461 (side-chain only); removes one N-linked 
glycosylation site compared to the majority of the 








CAP345 V75 (V->I); R350 (K->E) 
 






No known function 
 
No known function 
 
Residue immediately precedes the 
Leucine/Isoleucine zipper-like sequence of gp41  
 
Within the Leucine/Isoleucine zipper-like sequence 










CAP343 T31 (M->V) First amino acid residue of GP120; adjacent to the 
Env signal peptide cleavage site 
 
(200) 
CAP363 L21 (G->S) 
 
E32 (E->G) 
Amino acid 20 of signal peptide  
 






CAP326 V2 loop, residues not 
present in HXB2 (P->L) 
 
I284 (M->I) 
No known function 
 
 






CAP307 T194 (K->I) In the V1 loop adjacent to a coreceptor-specific site 
 
(197) 








V2 hypervariable loop  
 











V1 loop, adjacent to a coreceptor-specific site 
 
V2 hypervariable loop 
 
First residue of Loop D; adjacent to a neutralising 







CAP370 Q442 (N->S) Coreceptor binding site outside of the V3 loop and 









HXB2 Env gp160 position 
(change from T/F) 
Known function(s) of residue or region Reference(s)
* 






Fusion peptide of gp41 
 
First residue of LLP-1 
 







CAP357 S767 (C->S) 
 
 
L774- V778 (FILIA->LALVI) 
Residue preceding the LLP-2 domain of gp41; no 
known function 
 
Series of 4 mutations in the LLP-2; overlaps with the 





*Obtained from the HXB2 Genome Annotation document available on the Los Alamos website at 
http://www.hiv.lanl.gov/content/sequence/HIV/MAP/annotation.html and the N Glycosite tool 


































Figure A3D.1.  Phylogenetic analysis of full-length plasma- and isolate-derived env 
sequences of HIV-1 from the same time-point post-infection in each participant.  Nucleotide 
sequences were generated by limit dilution PCR amplification.  Sequences from 24 participants 
from both arms of the trial (PLB depicted in blue, TFV in red) were aligned to a CAPRISA 002 
cohort consensus and a maximum likelihood tree was generated.  Triangles were used to 
represent isolate sequences while circles were used to represent plasma sequences.  Only 
participants with full-length plasma-derived env sequences full-length sequences were used to 
generate this tree.  **denotes participants who were identified as having established infection as 











Figure A3D.2.  Phylogenetic analysis of truncated plasma- and isolate-derived env 
sequences of HIV-1 from the same time-point post-infection in each participant.  Nucleotide 
sequences were generated by limit dilution PCR amplification.  Sequences from 22 participants 
from both arms of the trial (PLB depicted in blue, TFV in red) were aligned to a CAPRISA 002 
cohort consensus and a maximum likelihood tree was generated.  Triangles were used to 
represent isolate sequences while circles were used to represent plasma sequences.  Sequences 
were truncated to the middle of gp41 within the env sequence due to a number of plasma-derived 
env sequences being only partially sequenced.  **denotes participants who were identified as 






Appendix 3E.  Isolate inhibition curves 
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Figure 3E.1.  Isolate inhibition with TFV, a reverse transcriptase inhibitor.  The graph shows 
the decrease in the percentage infectivity of isolates (y-axis) on TZM-bl cells with increasing TFV 
concentration (x-axis).  TFV arm isolate inhibition is represented as red curves while PLB arm 
isolate inhibition is depicted in blue.  BAL (black) and IIB (turquoise) isolates were used as control 
within each experiment.  As both controls are sensitive to TFV, they are inhibited as expected.  







Figure 3E.2.  Isolate inhibition with T20, a fusion inhibitor.  The graph shows the decrease in 
the percentage infectivity of isolates (y-axis) on TZM-bl cells with increasing T20 concentration 
(x-axis).  TFV arm isolate inhibition is represented as red curves while PLB arm isolate inhibition 
is depicted in blue.  BAL (black) and IIB (turquoise) isolates were used as control within each 
experiment.  As both controls are sensitive to T20 they behave as expected.  The figure was 
generated using GraphPad Prism. 
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Figure 3E.3.  Isolate inhibition with maraviroc, a non-competitive CCR5 binding inhibitor.  
The graph shows the decrease in the percentage infectivity of isolates (y-axis) on TZM-bl cells 
with increasing MVC concentration (x-axis).  TFV arm isolate inhibition is represented as red 
curves while PLB arm isolate inhibition is depicted in blue.  BAL (black) and IIB (turquoise) 
isolates were used as control within each experiment.  As BAL is a known R5-tropic virus it is 
inhibited as expected.  IIIB is an X4-tropic virus and is not sensitive to inhibition by MVC, as 
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Figure 3E.4.  Isolate inhibition with SK3, a competitive CD4 binding inhibitor.  The graph 
shows the decrease in the percentage infectivity of isolates (y-axis) on TZM-bl cells with 
increasing SK3 concentration (x-axis).  TFV arm isolate inhibition is represented as red curves 
while PLB arm isolate inhibition is depicted in blue.  BAL (black) and IIB (turquoise) isolates were 
used as control within each experiment.  Both controls are susceptible to inhibition by anti-CD4 
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Figure 3E.5.  Isolate inhibition with PSC-RANTES, a competitive CCR5 binding inhibitor.  
The graph shows the decrease in the percentage infectivity of isolates (y-axis) on TZM-bl cells 
with increasing PSC-RANTES concentration (x-axis).  TFV arm isolate inhibition is represented as 
red curves while PLB arm isolate inhibition is depicted in blue.  BAL (black) and IIB (turquoise) 
isolates were used as control within each experiment.  As BAL is a known R5-tropic virus it is 
inhibited as expected.  IIIB is an X4-tropic virus and is not sensitive to inhibition by PSC-RANTES, 
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Figure 3E.6.  Isolate inhibition with bicyclam JM-2987, a non-competitive CXCR4 binding 
inhibitor.  The graph shows the decrease in the percentage infectivity of isolates (y-axis) on TZM-
bl cells with increasing JM-2987 concentration (x-axis).  TFV arm isolate inhibition is represented 
as red curves while PLB arm isolate inhibition is depicted in blue.  BAL (black) and IIB (turquoise) 
isolates were used as control within each experiment.  As BAL is a known R5-tropic virus it is not 
inhibited, as expected.  IIIB is an X4-tropic virus and is sensitive to inhibition by JM-2987, as 

















Appendix 3F.  Inhibition of pseudoviruses with their corresponding isolate. 
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Figure 3F.  Inhibition curves of pseudoviruses and their corresponding isolate.  
Inhibition curves show the log of the drug concentration on the x-axis and the percentage 
inhibition on the y-axis.  Experiments were performed on TZM-bl cells with an incubation 
period of 48h after addition of the virus to the cells.  Cool colours represent participants 
from the placebo arm while warm colours represent those from the TFV arm.  On each 
figure, the darkly coloured curve (blue or red) represents inhibition of PSV growth while 
the lighter colour (turquoise or orange) shows inhibition of isolate replication.  This 
experiment was performed using eight PSVs for each of four inhibitors (labelled at the top 
of each set of inhibition curves).  Participant ID’s are indicated in each figure to the right 




























1.  UNAIDS. 2013. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. 
2.  Leclerc-Madlala S, Simbayi L, Cloete A. 2009. The Sociocultural Aspects of HIV/AIDS in 
South Africa 25 Years On. Psychosocial Perspectives. Springer Science + Business Media, 
LLC. 
3.  E. Ordóñez C, C. Marconi V. 2012. Understanding HIV Risk Behavior from a Sociocultural 
Perspective. J AIDS Clin Res 3:online. 
4.  Mbonye M, Nalukenge W, Nakamanya S, Nalusiba B, King R, Vandepitte J, Seeley J. 
2012. Gender inequity in the lives of women involved in sex work in Kampala, Uganda. J 
Int AIDS Soc 15 Suppl 1:1–9. 
5.  Leclerc-Madlala S. 2008. Age-disparate and intergenerational sex in southern Africa: the 
dynamics of hypervulnerability. AIDS 22 Suppl 4:S17-25. 
6.  Leclerc-Madlala S. 2009. Cultural scripts for multiple and concurrent partnerships in 
southern Africa: why HIV prevention needs anthropology. Sex Health 6:103. 
7.  Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntryre JA, Harlow SD. 2004. Gender-
based violence, relationship power, and risk of HIV infection in women attending 
antenatal clinics in South Africa. Lancet 363:1415–1421. 
8.  MacPherson EE, Sadalaki J, Njoloma M, Nyongopa V, Nkhwazi L, Mwapasa V, Lalloo 
DG, Desmond N, Seeley J, Theobald S. 2012. Transactional sex and HIV: understanding 
the gendered structural drivers of HIV in fishing communities in Southern Malawi. J Int 
AIDS Soc 15 Suppl 1:1–9. 
9.  Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. 2014. Estimating per-act 
HIV transmission risk: a systematic review. AIDS 28:1509–19. 
10.  Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. 2009. 
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis 
of observational studies. Lancet Infect Dis 9:118–129. 
11.  Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, 
Inambao M, Kilembe W, Farquhar C, Celum C, Partners in Prevention HSV/HIV 
Transmission Study Team. 2012. Determinants of per-coital-act HIV-1 infectivity 
among African HIV-1-serodiscordant couples. J Infect Dis 205:358–65. 
12.  Long EM, Martin HL, Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, Rakwar J, 
Mandaliya K, Overbaugh J. 2000. Gender differences in HIV-1 diversity at time of 
infection. Nat Med 6:71–5. 
13.  Barreto-de-Souza V, Arakelyan A, Margolis L, Vanpouille C. 2014. HIV-1 Vaginal 




14.  Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. 
Nature 464:217–23. 
15.  Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, 
Waiyaki P, Cheang M, Piot P, Ronald AR. 1991. Cofactors in male-female sexual 
transmission of human immunodeficiency virus type 1. J Infect Dis 163:233–9. 
16.  Shey MS, Garrett NJ, McKinnon LR, Passmore J-AS. 2015. The role of dendritic cells in 
driving genital tract inflammation and HIV transmission risk: are there opportunities to 
intervene? Innate Immun 21:99–112. 
17.  Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, 
Ngure K, Kiarie J, Coombs RW, Baeten JM, Partners in Prevention HSV/HIV 
Transmission Study Team. 2012. Use of hormonal contraceptives and risk of HIV-1 
transmission: a prospective cohort study. Lancet Infect Dis 12:19–26. 
18.  Royce RA, Seña A, Cates W, Cohen MS. 1997. Sexual transmission of HIV. N Engl J Med 
336:1072–1078. 
19.  Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, Goeman J, Behets F, Batter 
V, Alary M. 1993. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 
transmission in women: results from a cohort study. AIDS 7:95–102. 
20.  Pellett Madan R, Masson L, Tugetman J, Werner L, Grobler A, Mlisana K, Lo Y, Che D, 
Arnold KB, Abdool Karim SS, Passmore J-AS, Herold BC. 2015. Innate Antibacterial 
Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV 
Acquisition. AIDS Res Hum Retroviruses 31:1153–1159. 
21.  Masson L, Passmore J-AS, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson 
C, Little F, Mansoor LE, Naranbhai V, Lauffenburger D a., Ronacher K, Walzl G, 
Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool 
Karim QA, Abdool Karim SS. 2015. Genital Inflammation and the Risk of HIV Acquisition 
in Women. Clin Infect Dis 61:260–269. 
22.  Maartens G, Celum C, Lewin SR. 2014. HIV infection: epidemiology, pathogenesis, 
treatment, and prevention. Lancet 384:258–271. 
23.  Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, 
Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping L-H, 
Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart 
EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, 
Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 
2008. Identification and characterization of transmitted and early founder virus 
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105:7552–7. 




Heterosexual Transmission. Science 303:2019–2022. 
25.  Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, 
Manigart O, Mulenga J, Keele BF, Shaw GM, Hahn BH, Allen SA, Derdeyn CA, Hunter 
E. 2009. Inflammatory genital infections mitigate a severe genetic bottleneck in 
heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5:e1000274. 
26.  Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, 
Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, 
Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, 
Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, 
Korber BT, Hahn BH, Shaw GM. 2009. Genetic identity, biological phenotype, and 
evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. 
J Exp Med 206:1273–89. 
27.  Abrahams M-R, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping L-H, Athreya GS, 
Treurnicht FK, Keele BF, Wood N, Salazar-Gonzalez JF, Bhattacharya T, Chu H, 
Hoffman I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hide W, Cohen MS, 
Karim SA, Haynes BF, Shaw GM, Hahn BH, Korber BT, Swanstrom R, Williamson C. 
2009. Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus 
Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. J Virol 
83:3556–3567. 
28.  Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Learn 
GH, Morgan CJ, Schumacher JE, Haynes BF, Keele BF, Hahn BH, Shaw GM. 2010. Wide 
Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users. J Virol 
84:6241–6247. 
29.  Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, 
Learn GH, Morgan CJ, Schumacher JE, Hraber P, Giorgi EE, Bhattacharya T, Korber 
BT, Perelson AS, Eron JJ, Cohen MS, Hicks CB, Haynes BF, Markowitz M, Keele BF, 
Hahn BH, Shaw GM. 2010. High Multiplicity Infection by HIV-1 in Men Who Have Sex 
with Men. PLoS Pathog 6:e1000890. 
30.  Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Chohan BH, Kreiss JK, 
Overbaugh J. 2003. Infection with multiple human immunodeficiency virus type 1 
variants is associated with faster disease progression. J Virol 77:12921–6. 
31.  Shaw GM, Hunter E. 2012. HIV Transmission. Cold Spring Harb Perspect Med 
2:a006965–a006965. 
32.  Masharsky AE, Dukhovlinova EN, Verevochkin SV., Toussova OV., Skochilov RV., 
Anderson JA, Hoffman I, Cohen MS, Swanstrom R, Kozlov AP. 2010. A substantial 




St Petersburg, Russia. J Infect Dis 201:1697–702. 
33.  Weiss RA. 1993. How does HIV cause AIDS? Science 260:1273–9. 
34.  Levy JA. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 
57:183–289. 
35.  Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in 
HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167–70. 
36.  Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd 
JA, Saah AJ, Detels R, Phair JP, Rinaldo CR. 1997. Plasma viral load and CD4+ 
lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946–54. 
37.  Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, Richardson BA, 
Mandaliya K, Achola JON, Overbaugh J. 2006. Higher Set Point Plasma Viral Load and 
More-Severe Acute HIV Type 1 (HIV-1) Illness Predict Mortality among High-Risk HIV-1-
Infected African Women. Clin Infect Dis 42:1333–1339. 
38.  van’t Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier 
HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H. 1994. Macrophage-
tropic variants initiate human immunodeficiency virus type 1 infection after sexual, 
parenteral, and vertical transmission. J Clin Invest 94:2060–7. 
39.  Ping L-H, Joseph SB, Anderson JA, Abrahams M-R, Salazar-Gonzalez JF, Kincer LP, 
Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar 
MG, Iyer SS, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, 
Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Abdool 
Karim SS, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, 
Williamson C, Swanstrom R, CAPRISA Acute Infection Study and the Center for HIV-
AIDS Vaccine Immunology Consortium. 2013. Comparison of viral Env proteins from 
acute and chronic infections with subtype C human immunodeficiency virus type 1 
identifies differences in glycosylation and CCR5 utilization and suggests a new strategy 
for immunogen design. J Virol 87:7218–33. 
40.  Zhang Z. 1999. Sexual Transmission and Propagation of SIV and HIV in Resting and 
Activated CD4+ T Cells. Science 286:1353–1357. 
41.  Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in Coreceptor 
Use Correlates with Disease Progression in HIV-1–Infected Individuals. J Exp Med 
185:621–628. 
42.  Scarlatti G, Tresoldi E, Björndal Å, Fredriksson R, Colognesi C, Deng HK, Malnati MS, 
Plebani A, Siccardi AG, Littman DR, Fenyö EM, Lusso P. 1997. In vivo evolution of HIV-





43.  Long EM, Rainwater SMJ, Lavreys L, Mandaliya K, Overbaugh J. 2002. HIV type 1 
variants transmitted to women in Kenya require the CCR5 coreceptor for entry, 
regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 
18:567–76. 
44.  Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. 2005. 
Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants 
with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic 
Subtypes and May Impact Viral RNA Levels. J Virol 79:6528–6531. 
45.  Sagar M, Laeyendecker O, Lee S, Gamiel J, Wawer MJ, Gray RH, Serwadda D, 
Sewankambo NK, Shepherd JC, Toma J, Huang W, Quinn TC. 2009. Selection of HIV 
variants with signature genotypic characteristics during heterosexual transmission. J 
Infect Dis 199:580–9. 
46.  Gnanakaran S, Bhattacharya T, Daniels M. 2011. Recurrent signature patterns in HIV-1 
B clade envelope glycoproteins associated with either early or chronic infections. PLoS …. 
47.  Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, 
Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes 
JC, Galimidi RP, West AP, Bjorkman PJ, Wilen CB, Doms RW, O’Brien M, Bhardwaj N, 
Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. 2013. 
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci 110:6626–6633. 
48.  Deymier MJ, Ende Z, Fenton-May AE, Dilernia DA, Kilembe W, Allen SA, Borrow P, 
Hunter E. 2015. Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like 
Variants without Increased Replicative Capacity or Interferon-α Resistance. PLoS Pathog 
11:e1005154. 
49.  Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, 
Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn 
BH, Doms RW. 2011. Phenotypic and immunologic comparison of clade B 
transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 85:8514–27. 
50.  Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, Deymier MJ, 
Ende ZS, Klatt NR, DeZiel CE, Lin T-H, Peng J, Seese AM, Shapiro R, Frater J, Ndung’u 
T, Tang J, Goepfert P, Gilmour J, Price MA., Kilembe W, Heckerman D, Goulder PJR, 
Allen TM, Allen S, Hunter E. 2014. Selection bias at the heterosexual HIV-1 transmission 
bottleneck. Science 345:1254031–1254031. 
51.  Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, Giorgi EE, 
Mulenga J, Karita E, Korber BT, Allen S, Hart CE, Derdeyn CA, Hunter E. 2011. Role of 





52.  Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. 2010. HIV virology and 
pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita 46:5–14. 
53.  Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. 1992. Inhibition of 
furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358–61. 
54.  Gu M, Rappaport J, Leppla SH. 1995. Furin is important but not essential for the 
proteolytic maturation of gp160 of HIV-1. FEBS Lett 365:95–7. 
55.  Moulard M, Hallenberger S, Garten W, Klenk HD. 1999. Processing and routage of HIV 
glycoproteins by furin to the cell surface. Virus Res 60:55–65. 
56.  Earl PL, Doms RW, Moss B. 1990. Oligomeric structure of the human immunodeficiency 
virus type 1 envelope glycoprotein. Proc Natl Acad Sci 87:648–652. 
57.  Weiss CD, Levy JA, White JM. 1990. Oligomeric organization of gp120 on infectious 
human immunodeficiency virus type 1 particles. J Virol 64:5674–7. 
58.  Carr JM, Hocking H, Li P, Burrell CJ. 1999. Rapid and Efficient Cell-to-Cell Transmission 
of Human Immunodeficiency Virus Infection from Monocyte-Derived Macrophages to 
Peripheral Blood Lymphocytes. Virology 265:319–329. 
59.  Sattentau Q. 2008. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev 
Microbiol 6:815–26. 
60.  Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, Uchil PD, Heidecker 
G, Mothes W. 2013. Cell-to-Cell Transmission Can Overcome Multiple Donor and Target 
Cell Barriers Imposed on Cell-Free HIV. PLoS One 8:e53138. 
61.  McDonald D. 2003. Recruitment of HIV and Its Receptors to Dendritic Cell-T Cell 
Junctions. Science 300:1295–1297. 
62.  Hübner W, McNerney GP, Chen P, Dale BM, Gordon RE, Chuang FYS, Li X-D, Asmuth 
DM, Huser T, Chen BK. 2009. Quantitative 3D video microscopy of HIV transfer across T 
cell virological synapses. Science 323:1743–7. 
63.  Martin N, Welsch S, Jolly C, Briggs JAG, Vaux D, Sattentau QJ. 2010. Virological 
synapse-mediated spread of human immunodeficiency virus type 1 between T cells is 
sensitive to entry inhibition. J Virol 84:3516–27. 
64.  Felts RL, Narayan K, Estes JD, Shi D, Trubey CM, Fu J, Hartnell LM, Ruthel GT, 
Schneider DK, Nagashima K, Bess JW, Bavari S, Lowekamp BC, Bliss D, Lifson JD, 
Subramaniam S. 2010. 3D visualization of HIV transfer at the virological synapse 
between dendritic cells and T cells. Proc Natl Acad Sci 107:13336–13341. 
65.  Jolly C. 2004. HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent 
Synapse. J Exp Med 199:283–293. 
66.  Groot F, Welsch S, Sattentau QJ. 2008. Efficient HIV-1 transmission from macrophages 




67.  Jolly C, Mitar I, Sattentau QJ. 2007. Adhesion molecule interactions facilitate human 
immunodeficiency virus type 1-induced virological synapse formation between T cells. J 
Virol 81:13916–21. 
68.  Duncan CJA, Williams JP, Schiffner T, Gartner K, Ochsenbauer C, Kappes J, Russell 
RA, Frater J, Sattentau QJ. 2014. High-Multiplicity HIV-1 Infection and Neutralizing 
Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse. J Virol 
88:2025–2034. 
69.  Agosto LM, Uchil PD, Mothes W. 2015. HIV cell-to-cell transmission: effects on 
pathogenesis and antiretroviral therapy. Trends Microbiol 23:289–295. 
70.  Russell RA, Martin N, Mitar I, Jones E, Sattentau QJ. 2013. Multiple proviral integration 
events after virological synapse-mediated HIV-1 spread. Virology 443:143–149. 
71.  Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. 2011. Cell-to-cell 
spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95–
8. 
72.  Duncan CJA, Russell RA, Sattentau QJ. 2013. High multiplicity HIV-1 cell-to-cell 
transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS 
27:2201–2206. 
73.  Abela IA, Berlinger L, Schanz M, Reynell L, Günthard HF, Rusert P, Trkola A. 2012. 
Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed 
Antibodies. PLoS Pathog 8:e1002634. 
74.  Schiffner T, Sattentau QJ, Duncan CJA. 2013. Cell-to-cell spread of HIV-1 and evasion of 
neutralizing antibodies. Vaccine 31:5789–5797. 
75.  Wilen CB, Tilton JC, Doms RW. 2012. HIV: cell binding and entry. Cold Spring Harb 
Perspect Med 2:1–14. 
76.  Rangel HR, Weber J, Chakraborty B, Gutierrez A, Marotta ML, Mirza M, Kiser P, 
Martinez MA, Este JA, Quin ME. 2003. Role of the Human Immunodeficiency Virus Type 
1 Envelope Gene in Viral Fitness 77:9069–9073. 
77.  Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ. 
2005. Differences in the Fitness of Two Diverse Wild-Type Human Immunodeficiency 
Virus Type 1 Isolates Are Related to the Efficiency of Cell Binding and Entry. J Virol 
79:7121–7134. 
78.   FDA-Approved HIV Medicines | HIV/AIDS Fact Sheets | Education Materials | AIDSinfo. 
79.  Attia S, Egger M, Müller M, Zwahlen M, Low N. 2009. Sexual transmission of HIV 
according to viral load and antiretroviral therapy: systematic review and meta-analysis. 
AIDS 23:1397–1404. 




Lingappa JR, Celum C. 2010. Heterosexual HIV-1 transmission after initiation of 
antiretroviral therapy: a prospective cohort analysis. Lancet 375:2092–2098. 
81.  Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, Quinn TC, 
Serwadda D. 2011. HIV-1 transmission among HIV-1 discordant couples before and after 
the introduction of antiretroviral therapy. AIDS 25:473–7. 
82.  Del Romero J, Castilla J, Hernando V, Rodriguez C, Garcia S. 2010. Combined 
antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and 
prospective cohort study. BMJ 340:c2205–c2205. 
83.  Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, Coutinho A, 
Liechty C, Madraa E, Rutherford G, Mermin J. 2006. Changes in sexual behavior and 
risk of HIV transmission after antiretroviral therapy and prevention interventions in 
rural Uganda. AIDS 20:85–92. 
84.  Anglemyer A, Horvath T, Rutherford G. 2013. Antiretroviral Therapy for Prevention of 
HIV Transmission in HIV-Discordant Couples. JAMA 310:1619. 
85.  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, 
Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JHS, Godbole S V, Mehendale S, 
Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-
Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, 
Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, 
Celentano D, Essex M, Fleming TR. 2011. Prevention of HIV-1 Infection with Early 
Antiretroviral Therapy. N Engl J Med 365:493–505. 
86.  Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, 
Kanshana S, McIntosh K, Thaineua V, Perinatal HIV Prevention Trial (Thailand) 
Investigators. 2004. Single-dose perinatal nevirapine plus standard zidovudine to 
prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351:217–28. 
87.  Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, 
Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, 
Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. 2003. 
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for 
prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month 
follow-up of the HIVNET 012 randomised trial. Lancet (London, England) 362:859–68. 
88.  Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. 2008. 
Low rates of mother-to-child transmission of HIV following effective pregnancy 
interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22:973–81. 
89.  Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, 




Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker L-G, 
Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, 
Defechereux P, Postle B, Wang F, McConnell JJ, Zheng J-H, Lee J, Rooney JF, Jaffe HS, 
Martinez AI, Burns DN, Glidden DV. 2010. Preexposure Chemoprophylaxis for HIV 
Prevention in Men Who Have Sex with Men. N Engl J Med 363:2587–2599. 
90.  Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, 
Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, 
Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, 
Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, 
Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier 
M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, 
Haberer JE, Stevens WS, Lingappa JR, Celum C. 2012. Antiretroviral Prophylaxis for 
HIV Prevention in Heterosexual Men and Women. N Engl J Med 367:399–410. 
91.  Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, 
Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde 
M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson 
JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group. 2012. Antiretroviral 
preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 
367:423–34. 
92.  Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, 
Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, 
Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, 
Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D. 2012. 
Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med 
367:411–422. 
93.  Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, 
Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, 
Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts 
H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM. 2015. Tenofovir-Based 
Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med 
372:509–518. 
94.  Andrews CD, Heneine W. 2015. Cabotegravir long-acting for HIV-1 prevention. Curr 
Opin HIV AIDS 10:258–263. 
95.  Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, 
Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan 




Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 
329:1168–1174. 
96.  Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, 
Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker L-G, Jeenarain N, 
Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, Richardson BA, 
Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, 
Chirenje ZM, Nakabiito C, Taha TE, Jones J, Mayo A, Scheckter R, Berthiaume J, 
Livant E, Jacobson C, Ndase P, White R, Patterson K, Germuga D, Galaska B, Bunge K, 
Singh D, Szydlo DW, Montgomery ET, Mensch BS, Torjesen K, Grossman CI, 
Chakhtoura N, Nel A, Rosenberg Z, McGowan I, Hillier S. 2016. Use of a Vaginal Ring 
Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med NEJMoa1506110. 
97.  Karim QA, Baxter C, Karim SA. 2013. Topical Microbicides—Whatʼs New? JAIDS J 
Acquir Immune Defic Syndr 63:S144–S149. 
98.  Williams BG, Abdool Karim SS, Abdool Karim QA, Gouws E. 2011. Epidemiological 
impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 
58:207–10. 
99.  McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, 
Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, 
Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J. 2010. PRO2000 
vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 
301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (London, England) 
376:1329–37. 
100.  Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. 1998. A controlled trial 
of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted 
diseases. N Engl J Med 339:504–10. 
101.  Niruthisard S, Roddy RE, Chutivongse S. 1991. The effects of frequent nonoxynol-9 use 
on the vaginal and cervical mucosa. Sex Transm Dis 18:176–9. 
102.  Fichorova RN, Tucker LD, Anderson DJ. 2001. The molecular basis of nonoxynol-9-
induced vaginal inflammation and its possible relevance to human immunodeficiency 
virus type 1 transmission. J Infect Dis 184:418–28. 
103.  De Clercq E. 2007. Acyclic nucleoside phosphonates: Past, present and future. Biochem 
Pharmacol 73:911–922. 
104.  Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, 
Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. 2001. Phase I/II Trial of the 
Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in 





105.  Abdool Karim SS, Abdool Karim Q, Kharsany ABM, Baxter C, Grobler AC, Werner L, 
Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN. 2015. Tenofovir Gel for 
the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med 373:530–539. 
106.  Mansoor LE, Abdool Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, Amico 
KR, Fisher J, Fisher WA, Macqueen KM, Abdool Karim SS. 2014. Impact of an 
adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. 
AIDS Behav 18:841–8. 
107.  Mansoor LE, Abdool Karim QA, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, 
Grobler A, Abdool Karim SS. 2014. Adherence in the CAPRISA 004 tenofovir gel 
microbicide trial. AIDS Behav 18:811–9. 
108.  Delany-Moretlwe SA, Lombard C, Baron D, Panchia R, Myer L, Schwartz JL, Doncel 
GF, Gray GE, Rees H. 2015. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for 
HIV Prevention in Women, p. 90–91. In CROI, Seattle, Washington. 
109.  Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. 2003. Association between 
adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. 
Clin Infect Dis 37:1112–8. 
110.  Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, 
Wainberg MA. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to 
tenofovir in cell culture. AIDS 20:F9–F13. 
111.  White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. 2002. Molecular 
Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse 
Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function 
and Viral Replication Capacity. Antimicrob Agents Chemother 46:3437–3446. 
112.  Hoffmann CJ, Ledwaba J, Li J-F, Johnston V, Hunt G, Fielding KL, Chaisson RE, 
Churchyard GJ, Grant AD, Johnson JA, Charalambous S, Morris L. 2013. Resistance to 
tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 
Antivir Ther 18:915–20. 
113.  Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, de Oliveira T, Preiser W, Wood NT, 
Travers S, Shafer RW. 2013. Trends in Genotypic HIV-1 Antiretroviral Resistance 
between 2006 and 2012 in South African Patients Receiving First- and Second-Line 
Antiretroviral Treatment Regimens. PLoS One 8:e67188. 
114.  Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa M-YS, Ordonez C, 
Kuritzkes DR, Marconi VC. 2012. High rate of K65R for antiretroviral therapy-naive 





115.  Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos 
MA, Carmona SC, Stevens WS. 2015. High prevalence of the K65R mutation in HIV-1 
subtype C infected patients failing tenofovir-based first-line regimens in South Africa. 
PLoS One 10:e0118145. 
116.  von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, 
Cavassini M, Furrer H, Hirschel B, Vernazza PL, Rickenbach M, Ledergerber B, 
Günthard HF, Swiss HIV Cohort Study. 2008. Factors associated with the emergence of 
K65R in patients with HIV-1 infection treated with combination antiretroviral therapy 
containing tenofovir. Clin Infect Dis 46:1299–309. 
117.  Yang W-L, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V, Scherrer AU, Shilaih M, 
Hinkley T, Petropoulos C, Bonhoeffer S, Günthard HF. 2015. Persistence of 
Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral 
Genetic Backgrounds. PLoS Pathog 11:e1004722. 
118.  Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim QA, Li J-F, 
Kashuba ADM, Werner L, Passmore J-AS, Morris L, Heneine W, Johnson JA. 2014. 
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood 
compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel 
trial. J Infect Dis 209:1916–20. 
119.  Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, 
Williamson C, Morris L, Abdool Karim QA, Abdool Karim SS. 2015. HIV disease 
progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure 
prophylaxis trial. J Acquir Immune Defic Syndr 68:55–61. 
120.  Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool 
Karim QA, Carr WH, CAPRISA004 TRAPS team. 2012. Innate immune activation 
enhances hiv acquisition in women, diminishing the effectiveness of tenofovir 
microbicide gel. J Infect Dis 206:993–1001. 
121.  Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, 
Jaoko W, Overbaugh J. 2007. HIV-1 Subtype D Infection Is Associated with Faster 
Disease Progression than Subtype A in Spite of Similar Plasma HIV‐1 Loads. J Infect Dis 
195:1177–1180. 
122.  Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, 
Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J. 2002. Effect of Human 
Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease 
Progression in a Large Cohort of HIV‐1–Positive Persons in Uganda. J Infect Dis 
185:1244–1250. 




Gray CM, Morris L, Williamson C, AbdoolKarim SS. 2014. Rapid disease progression in 
HIV-1 subtype C-infected South African women. Clin Infect Dis 59:1322–1331. 
124.  Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk 
RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. 1992. Biological phenotype 
of human immunodeficiency virus type 1 clones at different stages of infection: 
progression of disease is associated with a shift from monocytotropic to T-cell-tropic 
virus population. J Virol 66:1354–60. 
125.  Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. 1994. MT-2 cell tropism as 
prognostic marker for disease progression in human immunodeficiency virus type 1 
infection [see comments]. J Clin Microbiol 32:364–370. 
126.  Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, 
Brumme ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, 
Brander C, Toth I, Arts EJ, Allen TM, Walker BD. 2009. HLA-B57/B*5801 human 
immunodeficiency virus type 1 elite controllers select for rare gag variants associated 
with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] 
recognition. J Virol 83:2743–55. 
127.  Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, 
Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD, 
Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker BD. 2010. 
Impaired replication capacity of acute/early viruses in persons who become HIV 
controllers. J Virol 84:7581–91. 
128.  Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, Markle TJ, Martin E, Block 
BL, Trocha A, Kadie CM, Allen TM, Pereyra F, Heckerman D, Walker BD, Brockman 
MA. 2011. Reduced Replication Capacity of NL4-3 Recombinant Viruses Encoding 
Reverse Transcriptase–Integrase Sequences From HIV-1 Elite Controllers. JAIDS J Acquir 
Immune Defic Syndr 56:100–108. 
129.  Mwimanzi P, Markle TJ, Martin E, Ogata Y, Kuang XT, Tokunaga M, Mahiti M, 
Pereyra F, Miura T, Walker BD, Brumme ZL, Brockman MA, Ueno T. 2013. 
Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology 10:1. 
130.  Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, Seoighe C, Treurnicht 
F, de Rosa DA, Hide W, Karim SA, Gray CM, Williamson C. 2008. Transmission of HIV-1 
CTL Escape Variants Provides HLA-Mismatched Recipients with a Survival Advantage. 
PLoS Pathog 4:e1000033. 
131.  Ntale R, Chopera D, Ngandu N, Abrahams M-R, Debra A, Mlotswa M, Werner L, 
Woodman Z, Mlisana K, Abdool Karim SS, Gray C, Williamson C. 2012. Beneficial HLA-




progression in HIV-1, subtype C infection. Retrovirology 9:O60. 
132.  Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, 
Bonhoeffer S, Gunthard HF. 2003. Human Immunodeficiency Virus Type 1 Fitness Is a 
Determining Factor in Viral Rebound and Set Point in Chronic Infection. J Virol 
77:13146–13155. 
133.  Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, Kopycinski J, 
Deymier MJ, Vanderford TH, Nganou-Makamdop K, Ende Z, Brooks K, Tang J, Yu T, 
Lakhi S, Kilembe W, Silvestri G, Douek D, Goepfert PA., Price MA., Allen SA, Paiardini 
M, Altfeld M, Gilmour J, Hunter E. 2015. Replicative fitness of transmitted HIV-1 drives 
acute immune activation, proviral load in memory CD4 + T cells, and disease progression. 
Proc Natl Acad Sci 201421607. 
134.  Hollingsworth TD, Laeyendecker O, Shirreff G, Donnelly CA, Serwadda D, Wawer MJ, 
Kiwanuka N, Nalugoda F, Collinson-Streng A, Ssempijja V, Hanage WP, Quinn TC, 
Gray RH, Fraser C. 2010. HIV-1 Transmitting Couples Have Similar Viral Load Set-Points 
in Rakai, Uganda. PLoS Pathog 6:e1000876. 
135.  Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, 
Deeks SG. 2010. HIV RNA level in early infection is predicted by viral load in the 
transmission source. AIDS 24:941–945. 
136.  Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu S-L, Rademeyer C, 
Learn GH, abdool Karim SS, Williamson C, Corey L, Margolick JB, Mullins JI. 2004. 
Dual HIV-1 infection associated with rapid disease progression. Lancet (London, 
England) 363:619–22. 
137.  Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Abdool Karim SS, Morris L, 
Williamson C. 2004. Incidence of HIV-1 dual infection and its association with increased 
viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect 
Dis 190:1355–9. 
138.  Valley-Omar Z, Sibeko S, Anderson JA, Goodier S, Werner L, Arney L, Naranbhai V, 
Treurnicht F, Abrahams M-R, Bandawe G, Swanstrom R, Abdool Karim QA, Abdool 
Karim SS, Williamson C. 2012. CAPRISA 004 tenofovir microbicide trial: no impact of 
tenofovir gel on the HIV transmission bottleneck. J Infect Dis 206:35–40. 
139.  Laeyendecker O, Redd AD, Nason M, Longosz AF, Abdool Karim QA, Naranbhai V, 
Garrett N, Eshleman SH, Abdool Karim SS, Quinn TC. 2015. Antibody Maturation in 
Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. 
J Infect Dis 212:754–759. 
140.   Avidity-Wikipedia Definition. 




Hanson D, Heneine W, Owen SM, García-Lerma JG. 2011. Delayed Maturation of 
Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV 
During Oral Pre-Exposure Prophylaxis. JAIDS J Acquir Immune Defic Syndr 57:355–362. 
142.  Kersh EN, Luo W, Zheng Q, Adams DR, Hanson D, Youngpairoj AS, Cong M, Butler K, 
Hendry RM, McNicholl JM, Heneine W, Garcia-Lerma JG. 2012. Reduced inflammation 
and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis 
206:770–9. 
143.  Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. 2003. Relationship 
between In Vitro Human Immunodeficiency Virus Type 1 Replication Rate and Virus 
Load in Plasma. J Virol 77:12105–12112. 
144.  Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, Prentice HA, Yue L, 
Vishwanathan SA, Kilembe W, Goepfert P, Price MA, Gilmour J, Mulenga J, Farmer P, 
Derdeyn CA, Tang J, Heckerman D, Kaslow RA, Allen SA, Hunter E. 2012. Role of 
transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 
pathogenesis. PLoS Pathog 8:e1003041. 
145.  Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW, Toossi Z, 
Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ. 2005. Changes in human 
immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J 
Virol 79:9006–18. 
146.  Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, 
Martin E, Naranbhai V, Karim SA, Karim QA, Brumme ZL, Ndung’u T, Williamson C, 
Brockman MA. 2013. No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or 
Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide 
Trial. PLoS One 8:e71758. 
147.  Garcia J V, Miller AD. 1991. Serine phosphorylation-independent downregulation of 
cell-surface CD4 by nef. Nature 350:508–11. 
148.  Piguet V, Wan L, Borel C, Mangasarian A, Demaurex N, Thomas G, Trono D. 2000. 
HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major 
histocompatibility complexes. Nat Cell Biol 2:163–7. 
149.  Gorry PR, McPhee DA, Verity E, Dyer WB, Wesselingh SL, Learmont J, Sullivan JS, 
Roche M, Zaunders JJ, Gabuzda D, Crowe SM, Mills J, Lewin SR, Brew BJ, Cunningham 
AL, Churchill MJ. 2007. Pathogenicity and immunogenicity of attenuated, nef-deleted 
HIV-1 strains in vivo. Retrovirology 4:66. 
150.  Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, Cunningham A, 
Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, 




Infected with Attenuated Human Immunodeficiency Virus Type 1 Containing Deletions in 
the nef and Long Terminal Repeat Regions. J Virol 81:9268–9278. 
151.  Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn 
CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, 
Haynes BF, Athreya GS, Korber BTM, Sharp PM, Shaw GM, Hahn BH. 2008. 
Deciphering human immunodeficiency virus type 1 transmission and early envelope 
diversification by single-genome amplification and sequencing. J Virol 82:3952–70. 
152.  Bagasra O, Pomerantz RJ. 1993. The role of CD8-positive lymphocytes in the control of 
HIV-1 infection of peripheral blood mononuclear cells. Immunol Lett 35:83–92. 
153.  DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. 1987. Analysis of 
mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 
7:379–387. 
154.  Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free 
retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:8392–6. 
155.  Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 
cell surface concentrations on infections by macrophagetropic isolates of human 
immunodeficiency virus type 1. J Virol 72:2855–64. 
156.  Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic 
murine leukemia virus contamination in TZM-bl cells does not affect the outcome of 
neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 
83:8289–92. 
157.  Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O’Brien WA, Ratner L, Kappes JC, Shaw 
GM, Hunter E. 2000. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion 
Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120. J 
Virol 74:8358–8367. 
158.  Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, 
Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in 
patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 
46:1896–905. 
159.  Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses 
constitutively released from cell lines used for human immunodeficiency virus research. J 
Virol 82:12585–8. 
160.  Spira AI, Ho DD. 1995. Effect of different donor cells on human immunodeficiency virus 
type 1 replication and selection in vitro. J Virol 69:422–429. 
161.  Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. 1999. A cell line-based 




either the CCR5 or the CXCR4 coreceptor. J Virol 73:8966–74. 
162.  Rohr O, Marban C, Aunis D, Schaeffer E. 2003. Regulation of HIV-1 gene transcription: 
from lymphocytes to microglial cells. J Leukoc Biol 74:736–49. 
163.  Terry VH, Johnston ICD, Spina CA. 2009. CD44 MicroBeads accelerate HIV-1 infection in 
T cells. Virology 388:294–304. 
164.  Vogt PK. 1967. DEAE-dextran: Enhancement of cellular transformation induced by avian 
sarcoma viruses. Virology 33:175–177. 
165.  Reed LJ, Muench H. 1938. A Simple Method of Estimating Fifty Percent Endpoints. Am J 
Epidemiol 27:493–497. 
166.   Limit dilution endpoint PCR for single molecules of DNA (Single Genome Amplification, 
SGA). 
167.  Larsson A. 2014. AliView: a fast and lightweight alignment viewer and editor for large 
datasets. Bioinformatics 30:3276–8. 
168.  Ranwez V, Harispe S, Delsuc F, Douzery EJP. 2011. MACSE: Multiple alignment of 
coding SEquences accounting for frameshifts and stop codons. PLoS One 6. 
169.  Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: Molecular 
Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30:2725–9. 
170.  Zhang M. 2004. Tracking global patterns of N-linked glycosylation site variation in highly 
variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. 
Glycobiology 14:1229–1246. 
171.  Giorgi EE, Funkhouser B, Athreya GS, Perelson AS, Korber BTM. 2010. Estimating 
time since infection in early homogeneous HIV-1 samples using a poisson model. BMC 
Bioinformatics 11:28. 
172.  Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, 
Kilby JM, Saag MS, Komarova NL, Nowak M a, Hahn BH, Kwong PD, Shaw GM. 2003. 
Antibody neutralization and escape by HIV-1. Nature 422:307–12. 
173.  Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, 
Schuitemaker H. 1992. Phenotype-associated sequence variation in the third variable 
domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66:3183–7. 
174.  Hoffman, TL, Doms RW. 1999. HIV-1 envelope determinants for cell tropism and 
chemokine receptor use. Mol Membr Biol 16:57–65. 
175.  Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, Churchill MJ, Purcell DFJ, 
Karlsson A, Albert J, Fenyö EM, Achour A, Gorry PR, Jansson M. 2008. Primary HIV-1 
R5 isolates from end-stage disease display enhanced viral fitness in parallel with 
increased gp120 net charge. Virology 379:125–134. 




tropism: concept, quantification, and clinical relevance. Clin Microbiol Infect 16:1532–
1538. 
177.  Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas 
KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, 
Matsen FA, Partners PrEP Study Team. 2015. Risk of drug resistance among persons 
acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure 
prophylaxis. J Infect Dis 211:1211–8. 
178.  Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Miller M. 2001. Tenofovir, 
adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 
1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses 
17:1167–1173. 
179.  Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, Doores KJ. 2015. Cell- and Protein-
Directed Glycosylation of Native Cleaved HIV-1 Envelope. J Virol 89:8932–8944. 
180.  Provine NM, Puryear WB, Wu X, Overbaugh J, Haigwood NL. 2009. The infectious 
molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 
exhibit significant differences in virion composition with only moderate differences in 
infectivity and inhibition sensitivity. J Virol 83:9002–7. 
181.  Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, 
Walkden-Brown SW, Nair VK. 2015. Imperfect Vaccination Can Enhance the 
Transmission of Highly Virulent Pathogens. PLoS Biol 13:e1002198. 
182.  Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Månson L, 
Asjö B, Wain-Hobson S. 1989. Temporal fluctuations in HIV quasispecies in vivo are not 
reflected by sequential HIV isolations. Cell 58:901–910. 
183.  Kusumi K, Conway B, Cunningham S, Berson A, Evans C, Iversen AK, Colvin D, Gallo 
M V, Coutre S, Shpaer EG. 1992. Human immunodeficiency virus type 1 envelope gene 
structure and diversity in vivo and after cocultivation in vitro. J Virol 66:875–85. 
184.  Aasa-Chapman MMI, Aubin K, Williams I, McKnight Á. 2006. Primary CCR5 only using 
HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. 
Virology 351:489–496. 
185.  Voronin Y, Chohan B, Emerman M, Overbaugh J. 2007. Primary isolates of human 
immunodeficiency virus type 1 are usually dominated by the major variants found in 
blood. J Virol 81:10232–41. 
186.  Dalmau J, Codoñer FM, Erkizia I, Pino M, Pou C, Paredes R, Clotet B, Martinez-Picado 
J, Prado JG. 2012. In–Depth Characterization of Viral Isolates from Plasma and Cells 





187.  Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, 
Maslankowski L, El-Sadr WM, Mayer KH. 2008. Acceptability of tenofovir gel as a 
vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens 
Health (Larchmt) 17:383–92. 
188.  Sokal DC, Abdool Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler 
A, Frolich J, Kharsany ABM, Miya N, Mlisana K, Maarshalk S, Abdool Karim SS. 2013. 
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the 
CAPRISA 004 Trial. Antivir Ther 18:301–310. 
189.  Parikh UM, Mellors JW. 2016. Should we fear resistance from tenofovir / emtricitabine 
preexposure prophylaxis ? Curr Opin HIV AIDS 11:49–55. 
190.  Hurt CB, Eron JJ, Cohen MS. 2011. Pre-exposure prophylaxis and antiretroviral 
resistance: HIV prevention at a cost? Clin Infect Dis 53:1265–1270. 
191.  Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee F-H, Didigu C a, Berro R, 
Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW. 2013. Transmitted/Founder 
and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of 
CCR5. J Virol 87:2401–2411. 
192.  Chenine A-L, Wieczorek L, Sanders-Buell E, Wesberry M, Towle T, Pillis DM, Molnar 
S, McLinden R, Edmonds T, Hirsch I, O’Connell R, McCutchan FE, Montefiori DC, 
Ochsenbauer C, Kappes JC, Kim JH, Polonis VR, Tovanabutra S. 2013. Impact of HIV-1 
backbone on neutralization sensitivity: neutralization profiles of heterologous envelope 
glycoproteins expressed in native subtype C and CRF01_AE backbone. PLoS One 
8:e76104. 
193.  Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 Envelope Glycoprotein Biosynthesis, 
Trafficking, and Incorporation. J Mol Biol 410:582–608. 
194.  Freed E, Martin M. 1996. Domains of the human immunodeficiency virus type 1 matrix 
and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 
70:341–351. 
195.  Murakami T, Freed EO. 2000. Genetic Evidence for an Interaction between Human 
Immunodeficiency Virus Type 1 Matrix and alpha -Helix 2 of the gp41 Cytoplasmic Tail. J 
Virol 74:3548–3554. 
196.  Sambrook J, Russell DW. 2001. Molecular Cloning: A Laboratory ManualThird Edit. Cold 
Spring Harbour Laboratory Press, Cold Spring Harbour, New York. 
197.  Korber B, Gnanakaran S. 2009. The implications of patterns in HIV diversity for 
neutralizing antibody induction and susceptibility. Curr Opin HIV AIDS 4:408–417. 
198.  Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A, Do Kwon Y, Scheid JF, Shi W, Xu L, 




PD. 2010. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody 
VRC01. Science 329:811–817. 
199.  Costin JM, Rausch JM, Garry RF, Wimley WC. 2007. Viroporin potential of the lentivirus 
lytic peptide (LLP) domains of the HIV-1 gp41 protein. Virol J 4:123. 
200.  Ellerbrok H, D’Auriol L, Vaquero C, Sitbon M. 1992. Functional tolerance of the human 
immunodeficiency virus type 1 envelope signal peptide to mutations in the amino-
terminal and hydrophobic regions. J Virol 66:5114–8. 
201.  Vogel EP, Curtis-Fisk J, Young KM, Weliky DP. 2011. Solid-State Nuclear Magnetic 
Resonance (NMR) Spectroscopy of Human Immunodeficiency Virus gp41 Protein That 
Includes the Fusion Peptide: NMR Detection of Recombinant Fgp41 in Inclusion Bodies in 
Whole Bacterial Cells and Structural Characterization of Pur. Biochemistry 50:10013–
10026. 
 
